amiodarone has been researched along with dronedarone in 410 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (1.71) | 18.2507 |
| 2000's | 92 (22.44) | 29.6817 |
| 2010's | 286 (69.76) | 24.3611 |
| 2020's | 25 (6.10) | 2.80 |
| Authors | Studies |
|---|---|
| Sen, S; Sinha, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adebesin, AM; Falck, JR; Fischer, R; Konkel, A; Lossie, J; Paudyal, MP; Puli, N; Schunck, WH; Vijaykumar, J; Wesser, T; Westphal, C; Zhu, C | 1 |
| Chatelain, P; Heyndrickx, JP; Hodeige, D; Manning, A | 1 |
| Chatelain, P; Heyndrickx, JP; Hodeige, D; Manning, A; Richard, J; Thisse, V | 1 |
| Chatelain, P; Finance, O; Manning, A | 1 |
| Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J | 1 |
| Beaufort, P; Chatelain, P; Clinet, M; Mattéazzi, JR; Meysmans, L | 1 |
| Leunissen, HD; van Opstal, JM; Verduyn, SC; Vos, MA; Wellens, HJ | 1 |
| Sarma, JS; Singh, BN; Sun, W | 2 |
| Aimond, F; Beck, L; Chérif, OK; Davy, JM; Gautier, P; Lorente, P; Nisato, D; Vassort, G | 1 |
| Altomare, C; Barbuti, A; Baruscotti, M; DiFrancesco, D; Viscomi, C | 1 |
| Djandjighian, L; Finance, O; Gautier, P; Nisato, D; Pastor, G; Planchenault, J | 1 |
| Gautier, P; Guillemare, E; Marion, A; Nisato, D | 1 |
| Camm, AJ | 1 |
| Agoston, M; Baláti, B; Delbruyère, M; Gautier, P; Hála, O; Iost, N; Németh, M; Nisato, D; Papp, JG; Pastor, G; Takács, J; Varró, A; Vereckei, A; Virág, L | 1 |
| Sarma, JS; Singh, BN | 1 |
| Barbé, C; Kreher, P; Rochetaing, A | 1 |
| de Groot, SH; Leunissen, JD; Molenschot, MM; Schoenmakers, M; van Der Hulst, FF; van Opstal, JM; Verduyn, SC; Vos, MA; Wellens, HJ | 1 |
| Bianconi, L; Castro, A; Santini, M | 1 |
| Carageorgiou, H; Cokkinos, D; Cokkinos, DD; Delbruyère, M; Malliopoulou, V; Mourouzis, I; Nikitas, N; Nisato, D; Pantos, C; Tzeis, S; Varonos, D | 1 |
| Bewick, NL; Buhagiar, KA; Delbridge, L; Fernandes, C; Hansen, PS; Hemsworth, PD; Pitt, AD; Rasmussen, HH; Whalley, DW | 1 |
| Bakker, O; Jong, WM; Kaptein, E; Van Beeren, HC; Visser, TJ; Wiersinga, WM | 1 |
| Bertrand, JP; Gautier, P; Guillemare, E; Marion, A; Nisato, D; Tourneur, Y | 1 |
| Barrére-Lemaire, S; Gautier, P; Lalevée, N; Nargeot, J; Richard, S | 1 |
| Karle, CA; Kathofer, S; Katus, HA; Kiehn, J; Kreye, VA; Schoels, W; Thomas, D; Wimmer, AB; Wu, K; Zhang, W; Zitron, E | 1 |
| Khan, MH | 1 |
| Singh, S | 1 |
| Caplain, H; Damy, T; Hulot, JS; Lechat, P; Pousset, F | 1 |
| Baritussio, A; Bigler, L; Bruttomesso, D; Duner, E; Follath, F; Ha, HR; Pettenazzo, A; Quaglino, D; Realdi, G | 1 |
| Doggrell, SA; Hancox, JC | 1 |
| Gautier, P; Gayraud, R; Guiraudou, P; Herbert, JM; Nisato, D; Pucheu, SC; Roccon, A | 1 |
| Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C | 1 |
| Hancox, JC; Milnes, JT; Ridley, JM; Witchel, HJ | 1 |
| Cokkinos, DV; Malliopoulou, V; Moraitis, P; Mourouzis, I; Paizis, I; Pantos, C; Sfakianoudis, K; Tzeis, S; Varonos, DD | 1 |
| Cheng, TO | 1 |
| Karle, CA; Kathofer, S; Thomas, D | 1 |
| Johanson, C; Larsson, F; Nilsson, M; Nyström, E; Tedelind, S; van Beeren, HC; Wiersinga, WM | 1 |
| Zareba, KM | 1 |
| Klein, HH | 1 |
| Ehrlich, JR; Hohnloser, SH; Wegener, FT | 1 |
| Schwender, T | 1 |
| Le Grand, B; Sablayrolles, S | 1 |
| Gaud, C; Radzik, D; Sarma, JS; Singh, BN; Wadhani, N | 1 |
| Coceani, M | 1 |
| Cokkinos, AD; Cokkinos, DV; Malliopoulou, V; Moraitis, P; Mourouzis, I; Paizis, I; Pantos, C; Xinaris, Ch | 1 |
| Dale, KM; White, CM | 1 |
| Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Korantzopoulos, P; Pantos, C; Tsalikakis, DG | 1 |
| Rowles, J; Tafreshi, MJ | 1 |
| Bakker, O; Christoffels, VM; Moorman, AF; Stoykov, I; van Beeren, HC; Wiersinga, WM | 1 |
| Banchs, JE; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, E; Samii, S; Wolbrette, DL | 2 |
| Biollaz, J; Buclin, T; Decosterd, LA; Galleyrand, J; Gaud, C; Rothuizen, LE; Tschuppert, Y | 1 |
| Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN | 1 |
| Ezekowitz, MD | 1 |
| Celestino, D; Elizari, MV; Medei, E; Moro, S; Sicouri, S | 1 |
| Cannon, CP; Morrow, JP; Reiffel, JA | 1 |
| Connolly, SJ; Crijns, HJ; Hohnloser, SH; Page, RL; Seiz, W; Torp-Petersen, C | 1 |
| Arlet, JB; Capron, L; Chouchana, L | 1 |
| Kayser, SR | 1 |
| Fink, AH | 1 |
| White, CM | 1 |
| Celestino, D; Elizari, MV; Ferreiro, M; Medei, E; Moro, S; Sicouri, S | 1 |
| Kimura, J; Watanabe, Y | 1 |
| Camm, AJ; Savelieva, I | 2 |
| Amlie, J; Carlsen, J; Crijns, H; Gøtzsche, O; Køber, L; Lévy, S; McMurray, JJ; Torp-Pedersen, C | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Cullington, D | 1 |
| Kowey, PR; Laughlin, JC | 1 |
| Han, TS; Vanderpump, MP; Williams, GR | 1 |
| Alings, A; Davy, JM; Herold, M; Hoglund, C; Radzik, D; Timmermans, A; Van Kempen, L | 1 |
| Preobrazhenskiĭ, DV | 4 |
| Conway, E; Kowey, PR; Musco, S | 1 |
| Kułakowski, P | 1 |
| Ehrlich, JR; Nattel, S | 1 |
| Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M | 4 |
| Verma, A | 1 |
| Zimetbaum, PJ | 1 |
| Hohnloser, SH | 2 |
| Krishnamoorthy, S; Lip, GY | 1 |
| Bolderman, RW; Hermans, JJ; Maessen, JG | 1 |
| Tejani, AM; Yih, V | 1 |
| Costantino, G; Podda, GM; Pugliano, M | 1 |
| Horner, SM | 1 |
| Floyd, J | 1 |
| Brachmann, J; Sinha, AM | 1 |
| Traynor, K | 1 |
| Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB | 1 |
| Hoy, SM; Keam, SJ | 1 |
| Kowey, PR; Patel, C; Yan, GX | 1 |
| Arora, BL; Arora, RR; Bhuriya, R; Patel, DD; Patel, PD; Singh, PP | 1 |
| Califf, RM; Hasselblad, V; Kong, DF; Peterson, ED; Piccini, JP; Washam, JB | 1 |
| Chan, PS; Nallamothu, BK; Oral, H | 1 |
| Camm, AJ; Falk, RH | 1 |
| Hamad, B; Kirkpatrick, P; Page, RL | 1 |
| DiMarco, JP; Mason, PK | 1 |
| Duray, GZ; Ehrlich, JR; Hohnloser, SH | 1 |
| Cohen-Lehman, J; Dahl, P; Danzi, S; Klein, I | 1 |
| Eskes, SA; Wiersinga, WM | 1 |
| Christiansen, CB; Køber, L; Torp-Pedersen, C | 2 |
| Garg, RK; Hundal, M | 1 |
| Prystowsky, EN | 1 |
| Gleason, PP; Kjesbo, NK; Schafer, JA | 1 |
| Cook, GE; Sasich, LD; Sukkari, SR | 2 |
| Lewalter, T | 2 |
| Cooper, JA | 1 |
| Clem, JR; Farver, DK; Fischer, JR; Johnson, TJ | 1 |
| Goette, A | 1 |
| Brachmann, J; Duray, G; Goette, A; Hohnloser, SH; Lewalter, T; Pittrow, D; Schmitt, J | 1 |
| Goette, A; Hohnloser, S; Kirch, W; Lewalter, T; Pittrow, D | 1 |
| Laufs, U; Röther, J | 1 |
| Dobrev, D; Nattel, S | 1 |
| Cingolani, E; Diamond, GA; Kaul, S; Singh, D | 1 |
| Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J | 1 |
| Rosei, EA; Salvetti, M | 1 |
| Sahadevan, J; Waldo, AL | 1 |
| Duray, GZ; Hohnloser, SH; Schmitt, J | 1 |
| Dorian, P | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A | 1 |
| Johnston, SS; Lin, J; Naccarelli, GV; Patel, PP; Schulman, KL | 1 |
| Baroletti, S; Catella, J; Cheng, JW; Ehle, M | 1 |
| Freudenberger, R; Levin, V; Marchlinski, FE; Shaaraoui, M | 1 |
| Franz, MR; Singh, SN | 1 |
| Coons, JC; Plauger, KM; Seybert, AL; Sokos, GG | 1 |
| Ghali, JK; Giles, T; Levine, TB; Radzik, D | 1 |
| Kuz'min, VS; Rozenshtraukh, LV | 1 |
| Crijns, H; Röther, J | 1 |
| Khoo, CW; Lim, HS; Lip, GY | 1 |
| Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D | 1 |
| Clem, JR | 1 |
| Hilleman, DE; Mooss, AN | 1 |
| Hofmann, PO; Oyetayo, OO; Rogers, CE | 1 |
| Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Sicouri, S | 1 |
| Connolly, SJ; Hohnloser, SH | 1 |
| Becker, RC; Fiuzat, M; Shirolkar, SC | 1 |
| Gil Núñez, A | 1 |
| Duray, GZ; Fink, A; Hohnloser, SH | 1 |
| Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N | 2 |
| Lip, GY; Pamukcu, B | 2 |
| Huikuri, HV; Raatikainen, MJ | 1 |
| Naccarelli, GV; Singh, BN | 1 |
| Cingolani, E; Singh, BN | 1 |
| Singh, BN | 1 |
| Gonska, BD | 1 |
| Brachmann, J; Ritscher, G; Simon Demel, K; Simon, H; Turschner, O | 1 |
| Sulimov, VA | 1 |
| Abdollah, H; Baranchuk, AM; Michael, KA; Miranda, RI; Redfearn, DP; Simpson, CS | 1 |
| Burkhardt, JD; Di Biase, L; Natale, A; Pelargonio, G; Santangeli, P | 1 |
| Albert, N; Anderson, JL; Buller, CE; Cannom, DS; Creager, MA; Crijns, HJ; Curtis, AB; Ellenbogen, KA; Estes, NA; Ettinger, SM; Ezekowitz, MD; Fuster, V; Guyton, RA; Halperin, JL; Hochman, JS; Jackman, WM; Jacobs, AK; January, CT; Kay, GN; Kushner, FG; Le Heuzey, JY; Lowe, JE; Ohman, EM; Olsson, S; Page, RL; Prystowsky, EN; Rydén, LE; Slotwiner, DJ; Stevenson, WG; Tamargo, JL; Tarkington, LG; Tracy, CM; Wann, LS; Yancy, CW | 1 |
| Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M | 1 |
| Saliba, W; Wazni, OM | 1 |
| Becker, R; Katus, HA; Schweizer, PA; Thomas, D | 1 |
| Bogdan, R; Goegelein, H; Ruetten, H | 1 |
| Connolly, SJ; Duray, GZ; Hohnloser, SH; Torp-Pedersen, C | 1 |
| Reiffel, JA | 3 |
| Eitan, R; Landshut, G; Lerer, B; Lifschytz, T; Ohayon, S; Zozulinsky, P | 1 |
| Capucci, A; Marinelli, A | 1 |
| Deshmukh, AJ; Karam, P; Mehta, J; Paydak, H; Singla, S | 1 |
| Naccarelli, GV | 2 |
| Kong, DF; Piccini, JP | 1 |
| Burke, JF; Mohmand-Borkowski, A; Penugonda, N | 1 |
| Brenner, R; Delacrétaz, E | 1 |
| Bushardt, RL; Jones, KW | 1 |
| Lunati, M; Pedretti, S | 1 |
| Caballero, R; Delpón, E; López-Farré, A; Tamargo, J | 1 |
| Brozou, V; Cokkinos, DV; Galanopoulos, G; Kostopanagiotou, G; Mourouzis, I; Pantos, C; Saranteas, T | 1 |
| Tang, YQ; Wang, XJ; Yang, Q; You, QD | 1 |
| Russo, AM | 1 |
| Mourouzis, I; Pantos, C | 1 |
| Broncel, M; Dorantowicz, R | 1 |
| Heusch, G; Skyschally, A | 1 |
| Dobrev, D | 1 |
| Mélon, P | 1 |
| Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C | 1 |
| Khanna, V; Reynolds, M; Reynolds, MR; Rutzen-Lopez, H; Vkhanna, V | 1 |
| Kolesińska, Z; Niedziela, M; Siuda, K | 1 |
| Le Heuzey, JY | 1 |
| Lombardi, F; Marzocchi, M | 1 |
| Arnaout, M; Beuzeboc, P; Lokiec, F; Moachon, L; Mongardon, N; Pène, F; Rezai, K; Vodovar, D | 1 |
| Aikens, TH; Ezekowitz, MD; Nagarakanti, R; Shapiro, T | 1 |
| Calkins, H; Lim, SH; Sinha, SK | 1 |
| Banach, M; Budrejko, S; Kozlowski, D; Lip, GY; Mikhailidis, DP; Raczak, G; Rysz, J | 1 |
| Haber, SL; Pogge, EK | 1 |
| Büchler, P; Estner, H; Huber, W; Joghetaei, N; Weirich, G | 1 |
| Baritussio, A; Bergonzini, V; Bigler, L; Calistri, A; Caretta, CM; Dal Zoppo, D; Del Vecchio, C; Faggin, E; Ha, HR; Nadai, M; Orlando, R; Palù, G; Pettenazzo, A; Piccoli, E; Salata, C | 1 |
| Doerfler, A; Engelhorn, T; Heusch, G; Schulz, R; Schwarz, MA | 1 |
| Chen, X; Dai, X; Xie, C; Yang, S; Zhong, D | 1 |
| Dai, WS; Gao, S; Juhaeri, J; Koren, AT; Schiappacasse, HA | 1 |
| Breithardt, G; Eckardt, L; Frommeyer, G; Kaiser, D; Milberg, P; Osada, N; Uphaus, T | 1 |
| Altomare, E; Bellanti, F; Blonda, M; Capitanio, N; Giudetti, AM; Gnoni, GV; Quinto, M; Romano, AD; Serviddio, G; Tamborra, R; Vendemiale, G | 1 |
| Nattel, S | 1 |
| Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR | 1 |
| Aderkast, C; Bochmann, S; Bramlage, P; Bukowska, A; Chilukoti, RK; Goette, A; Hammwöhner, M; Lendeckel, U; Mostertz, J; Röhl, FW; Schild, L; Sixdorf, A; Wiswedel, I; Wolke, C | 1 |
| Wehling, M | 2 |
| Lip, GY; Shantsila, A | 2 |
| Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C | 1 |
| Boiangiu, C; Cohen, M | 1 |
| Bruno, OD; Rizzo, LF | 1 |
| Fischer, GW; Trigo, P | 1 |
| Overbeck, P | 2 |
| Bui-Xuan, B; Chevalier, P; Morel, E; Timour, Q | 1 |
| Mullard, A | 1 |
| Heusch, G; Schulz, R | 1 |
| Ho, CM; Lam, CL; Siu, CW; Tse, HF; Wong, MP | 1 |
| Goldschlager, N | 1 |
| Boenigk, H; Braun-Dullaeus, RC; Esperer, HD; Genz, C; Herold, J; Kluba, K; Said, SM; Schmeisser, A; Wiedemann, AK | 2 |
| Benaim, G; Garcia-Marchan, Y; Hernandez-Rodriguez, V; Mujica-Gonzalez, S; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Silva, ML; Uzcanga, G | 1 |
| Blandino, A; Disertori, M; Gaita, F; Toso, E | 1 |
| Antenucci, C; Antonicelli, R; Bocconcelli, P; Boriani, G; Busacca, P; Capucci, A; Ciampani, N; Della Casa, S; Gabrielli, D; Galvani, M; Guerra, F; Margheri, M; Melandri, F; Modena, MG; Perna, GP; Pieri, P; Piovaccari, G; Pozzolini, A; Rapezzi, C; Villani, GQ | 1 |
| De Ponti, F; Mugelli, A | 1 |
| Åkerborg, Ö; Bégo-Le Bagousse, G; Lindgren, P; Nilsson, J; Rosenquist, M | 1 |
| Aikat, S; Chatterjee, S; Ghosh, J; Lichstein, E; Mukherjee, D | 1 |
| Eckardt, L; Vogler, J | 1 |
| Hiatt, WR; Kao, DP; Krantz, MJ | 1 |
| Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M | 1 |
| Becker, R; Katus, HA; Schmidt, C; Schweizer, PA; Thomas, D; Wiedmann, F | 1 |
| Avila Martínez, RJ; Benavides Mañas, PD; Catalán, JS; Díaz de Atauri Rodríguez, MJ; Hernández Voth, AR; Peñalver Paolini, CL | 1 |
| Hoffmeister, P; Peralta, A; Reynolds, M; Rosman, J | 1 |
| Duncker, D; Gardiwal, A; Klein, G; König, T; Lüsebrink, U; Oswald, H; Schreyer, H | 1 |
| Lindsay, BD | 1 |
| Ahmad, Y; Lip, GY | 1 |
| Saklani, P; Skanes, A | 1 |
| Boriani, G; Cars, T; De Ponti, F; Diemberger, I; Piccinni, C; Poluzzi, E; Puccini, A; Raschi, E; Wettermark, B | 1 |
| De Ferrari, GM; Dusi, V | 1 |
| Belardinelli, L; Kanas, AF; Nearing, BD; Pagotto, VP; Sobrado, MF; Verrier, RL; Zeng, D | 1 |
| Akhmedov, A; Beer, HJ; Breitenstein, A; Camici, GG; Duru, F; Luscher, TF; Riem, HH; Sluka, SH; Steffel, J; Stivala, S; Studt, JD; Tanner, FC | 1 |
| Biagi, C; Buccellato, E; Melis, M; Montanaro, N; Motola, D; Venegoni, M | 1 |
| Botto, GL; Campana, C; Mariconti, B; Pentimalli, F; Russo, G | 1 |
| Blum, K; Bouitbir, J; Felser, A; Krähenbühl, S; Lindinger, PW | 1 |
| Bai, R; Lin, L | 1 |
| Levin, V; Martinez, MW; Nanda, S | 1 |
| Bollmann, A; Hindricks, G; Husser, D; John, S; Kornej, J; Löbe, S; Salmas, J; Sörnmo, L; Stridh, M | 1 |
| Adamski, H; Chevrant-Breton, J; Dupuy, A; Le Gall, F; Miquel, J; Oger, E; Pollard, E | 1 |
| Salam, AM | 1 |
| Bauman, JL | 1 |
| Adlan, AM; Lip, GY | 1 |
| Aliot, E; Capucci, A; Connolly, S; Crijns, H; Hohnloser, S; Immordino, L; Kowey, P; Radzik, D; Roy, D | 1 |
| Chang, SL; Chen, SA; Chen, YC; Chen, YJ; Hanafy, DA; Kao, YH; Lin, YK; Lu, YY | 1 |
| Johnson, KG; Selvaraj, V | 1 |
| Czarnywojtek, A; Florek, E; Hen, K; Ruchała, M; Stangierski, A; Warmuz-Stangierska, I; Zdanowska, J | 1 |
| Bollmann, A; Hindricks, G; Husser, D; John, S; Kornej, J; Löbe, S; Salmáš, J | 1 |
| Blomström-Lundqvist, C; Dagres, N; Lewalter, T; Lip, GY; Pison, L; Proclemer, A | 1 |
| Galanopoulos, G; Kostakou, E; Mantzouratou, P; Mourouzis, I; Pantos, C | 1 |
| Aves, T; Dorian, P; Fujii, H; Glover, BM; Hu, X; Leong-Poi, H; Ramadeen, A; Zou, L | 1 |
| Berg, J; Connolly, S; Lindgren, P; Sauriol, L | 1 |
| Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T | 1 |
| Belardinelli, L; Machado, AD; Nearing, BD; Sobrado, LF; Varone, BB; Verrier, RL; Zeng, D | 1 |
| Braun-Dullaeus, RC; Esperer, HD; Genz, C; Kluba, K; Rauwolf, T; Said, SM; Schmeisser, A | 1 |
| Leaver, L; Maruthappu, M; Wayne, RP; Young, C | 1 |
| Cinnamond, N; Connolly, M; Damani, L; Hussey, S; Menown, IB | 1 |
| Jahn, S; Lackner, C; Stauber, RE; Zollner, G | 1 |
| Gonzalez, JE; Krantz, MJ; Sauer, WH | 1 |
| Cholleti, VK; Pydimarry, SP; Vangala, RR | 1 |
| Alexander, S; Braun-Dullaeus, RC; Esperer, HD; Hahn, J; Said, SM | 1 |
| Belardinelli, L; Kanas, AF; Machado, AD; Nearing, BD; Pagotto, VP; Sobrado, LF; Sobrado, MF; Varone, BB; Verrier, RL; Zeng, D | 1 |
| Morley, GE; Park, DS | 1 |
| Elpern, DJ; Ladizinski, B | 1 |
| Connolly, SJ; Crijns, HJ; Hohnloser, SH; Naditch-Brûlé, L; Page, RL; Pisters, R; Torp-Pedersen, C | 1 |
| Alexandre, J; Beygui, F; Manrique, A; Milliez, P; Puddu, PE; Rouet, R | 1 |
| Hu, ZY; Zhao, Y | 1 |
| Boriani, G; Botto, GL; Brignole, M; Calò, L; Calvi, V; Capucci, A; De Ponti, R; De Simone, A; Delise, P; Di Biase, M; Lombardi, F; Lunati, M; Raviele, A; Santomauro, M; Senni, M; Stabile, G; Themistoclakis, S; Tritto, M; Volpe, M | 1 |
| Chen, SA; Chen, YJ; Hsieh, MH; Huang, JH; Lin, YK | 1 |
| Goldberger, JJ; Teme, T | 1 |
| Caubel, P; Dai, W; Juhaeri, J; Koren, A; Tcherny-Lessenot, S; Thammakhoune, J; Wu, C; Wu, J | 1 |
| Benaim, G; Casanova, P; Concepcion, JL; Hernandez-Rodriguez, V; Liu, YL; Mujica-Gonzalez, S; Oldfield, E; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Suarez, AI | 1 |
| Ravens, U | 1 |
| Clarke, S; Flego, G; Haupt, E; Iannone, P; Magrini, N; Minardi, M; Truglio, P | 1 |
| Jhaveri, M; Kim, MH; Koren, A; Lin, J | 1 |
| Atenchong, N; Becker, S; Ciesek, S; Dahlmann, F; David, S; Gehring, G; Manns, MP; Mittler, E; Pöhlmann, S; Rohrmann, K; von Hahn, T; Vondran, FW | 1 |
| Friberg, L | 1 |
| Connolly, SJ; Halperin, JL; Hohnloser, SH; John Camm, A; Radzik, D | 1 |
| Kim, J; Lee, EJ | 1 |
| Doiny, D; Estrada, A; Figueroa, J; Filgueiras-Rama, D; Merino, JL; Páez, JL | 1 |
| Kowey, PR; Naccarelli, GV | 1 |
| Bouitbir, J; Donzelli, M; Felser, A; Krähenbühl, S; Morand, R; Schnell, D; Stoller, A; Terracciano, L | 1 |
| Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ | 1 |
| Brocks, DR; Gabr, RQ; Jardan, YA | 1 |
| Katus, HA; Koepple, C; Scherer, D; Scholz, EP; Seyler, C; Thomas, D; Xynogalos, P; Zitron, E | 1 |
| Crespo, M; Echeverría, D; Marin-Casino, M; Mir, M; Pascual, J; Pérez-Sáez, MJ | 1 |
| Carlé, A; Olsen, JS; Thomsen, HH | 1 |
| Bianco, D; Bizzarri, N; Brunelli, C; Ferrero, S; Parodi, A; Rosa, GM; Valbusa, A; Zawaideh, C | 1 |
| Barthel, P; Dössel, O; Loewe, A; Lutz, Y; Schmidt, G; Scholz, EP; Seemann, G; Sinnecker, D; Wilhelms, M | 1 |
| Camm, AJ; Connolly, SJ; Gao, P; Halperin, JL; Hohnloser, SH; Radzik, D | 1 |
| Parekh, JM; Sanyal, M; Shrivastav, PS; Yadav, M | 1 |
| Agra, Y; Moreno-Gómez, AM; Otero, MJ; Santos-Ramos, B | 1 |
| Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D | 1 |
| Al-Khatib, SM; Allen LaPointe, NM; Dai, D; Peterson, ED; Piccini, JP; Thomas, L | 1 |
| Figulla, HR; Franz, M; Gecks, T; Jung, C; Kühnert, H; Prochnau, D; Schliemann, S | 1 |
| Boulenc, X; Djebli, N; Fabre, D; Fabre, G; Hurbin, F; Sultan, E | 1 |
| Boddy, A; DiMarco, JP; Ellenbogen, KA; Ezekowitz, MD; Geba, GP; Kaszala, K; Koren, A; P, GG | 1 |
| Breithardt, G; Dechering, DG; Eckardt, L; Fehr, M; Frommeyer, G; Kochhäuser, S; Milberg, P; Schulze Grotthoff, J; Stypmann, J | 1 |
| Benninger, G; Bosch, RF; Goette, A; Paar, WD; Pittrow, D; von Stritzky, B | 1 |
| Bajer, M; Braun-Dullaeus, RC; Esperer, HD; Hahn, J; Said, SM | 1 |
| Aguilar, C | 1 |
| Bronder, E; Garbe, E; Haverkamp, W; Huemer, M; Klimpel, A; Sarganas, G | 1 |
| Han, SD; Jang, SW; Jung, HJ; Jung, SW; Kang, MJ; Kim, BM; Son, M | 1 |
| Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M | 1 |
| Ahuja, N; Casto, A; Nguyen, DV; Stack, S | 1 |
| Cereza, G; Figueras, A; Tarapués, M | 1 |
| Checura, C; Comin, MJ; Donadío, LG; Fernandez, C; García, LC; Orgueira, H; Santos, M | 1 |
| Han, SD; Jang, SW; Jung, SW; Kang, MJ; Kim, BM; Son, M | 1 |
| Biagi, C; Conti, V; Donati, M; Fortino, I; Melis, M; Motola, D; Vaccheri, A; Venegoni, M | 1 |
| Bukowska, A; Evert, M; Goette, A; Kühn, JP; Lendeckel, U; Linke, J; Peters, B; Utpatel, K; Wolke, C | 1 |
| Belardinelli, L; Camm, AJ; Karwatowska-Prokopczuk, E; Kowey, P; Olmsted, A; Reiffel, JA; Rosero, S; Zareba, W; Zeng, D | 1 |
| Adelstein, E; Alam, MB; Jain, SK; Khattak, F; Leef, G; Munir, MB; Patel, D; Qin, D; Rattan, R; Saba, S | 1 |
| Buranakarl, C; Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S | 1 |
| Ader, P; Arif, SA; Drury, R | 1 |
| Chai, CL; Chan, EC; Chia, YM; Hong, Y; Koh, SK; Kojodjojo, P; Venkatesan, G; Yeo, RH; Zhou, L | 1 |
| Carballido, EM; Dow, EN; Horsley-Silva, JL; Lindor, KD; Menias, CO; Smith, ML; Vargas, HE | 1 |
| Avery, S; Edey, AJ; Medford, AR; Thornton, D | 1 |
| Bali, A; Bansal, G; Chadha, R | 2 |
| Chen, KH; Du, XL; Jin, MW; Li, GR; Liu, H; Sun, HY; Wang, Y; Xiao, GS; Xu, XH; Yang, L | 1 |
| Capucci, A; Guerra, F; Matassini, MV; Scappini, L; Urbinati, A | 1 |
| Del Rio, C; Hamlin, RL; Kijtawornrat, A; Saengklub, N; Sawangkoon, S; Youngblood, B | 1 |
| Chai, CL; Chan, EC; Hong, Y; Karkhanis, A; Koh, SK; Kojodjojo, P; Lam, HY; Venkatesan, G; Zhou, L | 1 |
| Belardinelli, L; Braun, I; Danner, BC; Dobrev, D; Fischer, TH; Frey, N; Gummert, J; Hartmann, N; Hasenfuss, G; Maier, LS; Mason, FE; Pabel, S; Renner, A; Schotola, H; Sossalla, S; Voigt, N | 1 |
| Hohnloser, SH; Vamos, M | 1 |
| Brocks, DR; Jardan, YA | 1 |
| Chen, SJ; Jiang, LQ; Ran, Z; Xu, JJ; Ying, W; Zhao, SG | 1 |
| Andrade, JG; Nattel, S; Tadros, R | 1 |
| Ahsan, SY; Di Mario, C; Hayward, C; Lyon, AR; Patel, HC; Patel, K; Rowland, E | 1 |
| Brent Mitchell, L; Kuriachan, V; Rizkallah, J | 1 |
| Ogasahara, M; Okitsu, T; Wada, A | 1 |
| Brookes, C; Lock, J; Patel, JP; Patel, RK | 1 |
| Bollmann, A; Hindricks, G; Husser, D; John, S; Kornej, J; Löbe, S | 1 |
| Ehrlich, JR; Kaess, BM | 1 |
| Arceluz, M; Escobar, C; López-Sendón, JL; Merino, JL; Montes de Oca, R; Mori, R | 1 |
| Biffi, M; Boriani, G; Diemberger, I; Lorenzetti, S; Martignani, C; Massaro, G; Reggiani, MLB; Ziacchi, M | 1 |
| Nguyen, E; White, CM | 1 |
| Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Leitz, P; Puckhaber, D; Reinke, F | 1 |
| Burstein, ES; Ellis, J; Elmslie, G; Jayasuriya, GM | 1 |
| Ahmad, N; Badshah, SL; Farman, A; Khan, K; Ur Rahman, A; Ur Rashid, H | 1 |
| Ali, I; Brouwer, KLR; Lu, Y; Swaan, PW; Welch, MA | 1 |
| Teng, W; Wang, F; Xian, H; Yang, D; Zhang, M | 1 |
| Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S | 1 |
| Baek, IH; Kim, MS | 1 |
| Aronow, WS; Khan, MH; Rochlani, Y | 1 |
| Badimon, JJ; Halperin, JL; Santos-Gallego, CG; Smith, DA; Zafar, MU | 1 |
| Delgado-Baeza, E; Delgado-Martos, MJ; Desco, M; Gomez de Diego, JJ; Muñoz-Valverde, D; Quintana-Villamandos, B; Soto-Montenegro, ML | 1 |
| Baylon, JL; Denisov, IG; Grinkova, YV; Sligar, SG; Tajkhorshid, E | 1 |
| Goswami, A; Sen, C; Som, A | 1 |
| Chen, S; Guo, L; Ning, B; Ren, Z; Yu, D | 1 |
| Dai, W; Gandhi, S; Juhaeri, J; Kechemir, H; Lin, S; Tcherny-Lessenot, S; Wang, Y; Wu, C | 1 |
| Benaim, G; Hejchman, E; Hernández-Rodríguez, V; Pinto-Martinez, A; Rodríguez-Durán, J | 1 |
| Ehrlich, JR | 1 |
| Abenhaim, L; Benichou, J; Grimaldi-Bensouda, L; Larrey, D; Lohse, AW; Poynard, T; Rossignol, M; Schott, E; Wedemeyer, H; Wiegand, J | 1 |
| Dilaveris, P; Tousoulis, D | 1 |
| Afanasiev, SA; Kondratieva, DS; Popov, SV | 1 |
| Belur Nagaraj, A; DiFeo, A; Joseph, P; Kovalenko, O; Wang, Q; Xu, R | 1 |
| Babu Dasari, J; Battaini, F; Bernardini, S; De Lorenzo, A; Intorcia, A; Merra, G; Morgagni, R; Perrone, MA; Romeo, F; Sergi, D | 1 |
| Packer, M | 1 |
| Acosta-Martínez, J; Arana-Rueda, E; Frutos-López, M; Pedrote, A | 1 |
| Li, F; Li, M; Li, Z; Luo, D; Qiao, J; Yu, F; Yu, Y; Zhang, J | 1 |
| Bhatt, DL; Camm, AJ; Le Heuzey, JY; Lombardi, F; Martinez, JM; Naccarelli, GV; Naditch-Brûlé, L; Tamargo, J | 1 |
| Maharshak, I; Paul, M; Steiner, H | 1 |
| Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ | 1 |
| Chan, ECY; Chin, SY; Tan, HL; Tang, LWT | 1 |
| Hayashi, T; Ijiri, Y; Kato, R | 1 |
| Boeken, U; Dalyanoĝlu, H; Lichtenberg, A; Makimoto, H; Sipahi, FN; Sugimura, Y; Yilmaz, E | 1 |
| Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP | 1 |
| Desai, NR; Everhart, A; Jena, A; Karaca-Mandic, P; Ross, JS; Shah, N; Smith, LB; Stecher, C | 1 |
| Abenhaim, L; Botto, GL; Breithardt, G; de Abajo, FJ; Grimaldi-Bensouda, L; Khachatryan, A; Kirchhof, P; Merino, JL; Stambler, B | 1 |
| Ma, CS; Sun, YH; Wu, SL | 1 |
| Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J | 1 |
| Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J | 1 |
| Kowey, PR; McKindley, DS; Naccarelli, GV; Reiffel, JA; Stewart, J; Thind, M | 1 |
| Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q | 1 |
| Benaim, G; Benchimol, M; de Souza, TG; de Souza, W | 1 |
| Bigot, G; Bunch, TJ; Handelsman, Y; Konigsberg, L; Kowey, PR; Rodbard, HW; Steinberg, BA; Thind, M; Wieloch, M | 1 |
| Bai, R; Lin, JL; Ma, C; Nam, GB; Stewart, J; Sun, Y; Wieloch, M; Zhu, J | 1 |
| Bigot, G; Blomström-Lundqvist, C; Hohnloser, SH; McKindley, DS; Naccarelli, GV; Wieloch, M | 1 |
| Charland, S; Faith, L; Ken-Opurum, J; Park, S; Preblick, R; Revel, A; Srinivas, SS; Vadagam, P | 1 |
| Chang, SH; Chen, SW; Huang, CH; Huang, YC; Huang, YT; Hung, KC; Kuo, CF; Tu, HT; Wang, CL; Wu, VC | 1 |
| Blomström-Lundqvist, C; Camm, AJ; Crotty, C; Fazeli, MS; Kowey, PR; Kreidieh, B; Singh, JP; Turakhia, MP | 1 |
| Blomström-Lundqvist, C; Camm, AJ; Din, N; Fan, J; Kabadi, S; Kowey, P; Pundi, K; Rashkin, J; Sandhu, AT; Singh, JP; Turakhia, MP; Wieloch, M | 1 |
107 review(s) available for amiodarone and dronedarone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical differences between the newer antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sulfonamides | 2000 |
Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Dronedarone; Electrocardiography; Electrophysiology; Heart; Humans; Ion Channels; Pacemaker, Artificial; Sotalol | 2001 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2002 |
Oral class III antiarrhythmics: what is new?
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides; Tachycardia, Supraventricular; Tachycardia, Ventricular; Treatment Outcome | 2004 |
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Indoles; Oxazines; Phenethylamines; Piperazines; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides | 2004 |
Dronedarone: an amiodarone analogue.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Dronedarone; Drug Evaluation, Preclinical; Humans | 2004 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modality Therapy; Defibrillators, Implantable; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazolidines; Ion Transport; Life Tables; Membrane Potentials; Meta-Analysis as Topic; Phenethylamines; Piperazines; Risk Assessment; Sotalol; Sulfonamides; Survival Analysis; Torsades de Pointes; Treatment Outcome | 2004 |
The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Ion Channels | 2005 |
[Dronedarone--a new therapeutic option for controlling atrial rhythm and ventricular frequency].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Function; Creatinine; Dose-Response Relationship, Drug; Dronedarone; Electrophysiology; Humans; Secondary Prevention; Ventricular Function | 2006 |
Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Forecasting; Heart Rate; Humans; Practice Patterns, Physicians'; Treatment Outcome | 2006 |
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dronedarone; Humans | 2006 |
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availability; Clinical Trials as Topic; Dronedarone; Drug Interactions; Half-Life; Humans | 2007 |
Dronedarone: drondarone, SR 33589, SR 33589B.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Interactions; Humans; Potassium Channel Blockers | 2007 |
A review of the investigational antiarrhythmic agent dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drugs, Investigational; Humans; Ion Channels; Membrane Potentials; Molecular Structure | 2007 |
New antiarrhythmic treatment of atrial fibrillation.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbazoles; Carvedilol; Cyclopropanes; Dronedarone; Fatty Acids, Omega-3; Furans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oligopeptides; Organic Chemicals; Peptidyl-Dipeptidase A; Potassium Channel Blockers; Propanolamines; Purinergic P1 Receptor Agonists | 2007 |
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Evaluation; Heart Rate; Humans; Sinoatrial Node; Treatment Outcome | 2007 |
Dronedarone: in quest of the ideal antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Clinical Trials, Phase III as Topic; Dronedarone; Drug Interactions; Electrophysiology; Humans; Safety; Treatment Outcome | 2007 |
Dronedarone: a new treatment for atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dronedarone; Humans | 2008 |
Benzofuran derivatives and the thyroid.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Dronedarone; Humans; Hypothyroidism; Receptors, Thyroid Hormone; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2009 |
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazolidines; Piperazines; Pyrrolidines | 2008 |
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans; Pyrrolidines | 2009 |
Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans | 2009 |
[Dronedarone: the new antiarrythmic agent?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Conduction System; Heart Rate; Humans; Models, Cardiovascular | 2009 |
Dronedarone: a promising alternative for the management of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Heart Rate; Humans; Randomized Controlled Trials as Topic | 2009 |
Dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Drug Interactions; Humans; Intestinal Absorption; Meta-Analysis as Topic; Randomized Controlled Trials as Topic | 2009 |
Dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Ion Channels; Kaplan-Meier Estimate | 2009 |
Dronedarone for atrial fibrillation: a new therapeutic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Heart Rate; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Heart Rate; Humans; Randomized Controlled Trials as Topic; Sinoatrial Node; Treatment Outcome | 2009 |
New pharmacological agents for arrhythmias.
Topics: Acetanilides; Adenosine A1 Receptor Agonists; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Benzofurans; Clinical Trials as Topic; Dronedarone; Humans; Ivabradine; Piperazines; Pyrrolidines; Ranolazine | 2009 |
Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.
Topics: Adrenergic Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Ion Channels; Randomized Controlled Trials as Topic; Vasodilator Agents | 2010 |
Effects of amiodarone therapy on thyroid function.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Humans; Hypothyroidism; Iodine; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2010 |
Amiodarone and thyroid.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Female; Humans; Hypothyroidism; Male; Pregnancy; Pregnancy Complications, Cardiovascular; Thyroid Function Tests; Thyroid Gland; Thyrotoxicosis; Thyrotropin | 2009 |
Efficacy and safety of dronedarone: a review of randomized trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Failure; Heart Rate; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2010 |
Dronedarone--a new alternative for management of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Heart Failure; Heart Rate; Humans; Patents as Topic; Secondary Prevention | 2010 |
Dronedarone: current evidence and future questions.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dronedarone; Drug Interactions; Evidence-Based Medicine; Humans; Patient Selection; Risk Assessment; Treatment Outcome | 2010 |
Dronedarone: a safety comparison to amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Dronedarone; Drug Approval; Drug Interactions; Drug Monitoring; Humans; United States; United States Food and Drug Administration | 2010 |
[Current antiarrhythmic drug therapy in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
[Clinical profile of the new antiarrhythmic drug dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Administration Schedule; Electrocardiography; Humans; Kaplan-Meier Estimate; Randomized Controlled Trials as Topic; Stroke | 2010 |
[Clinical pharmacology and electrophysiological properties of dronedarone].
Topics: Adrenergic Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Calcium Channels; Disease Models, Animal; Dronedarone; Electrocardiography; Half-Life; Humans; Metabolic Clearance Rate; Sodium Channels | 2010 |
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Drug Therapy, Combination; Humans; Pyridines; Risk Factors; Stroke; Survival Rate; Thrombin; Vitamin K | 2010 |
New antiarrhythmic drugs for treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Dronedarone; Humans; Piperazines; Pyrrolidines; Ranolazine; Renin-Angiotensin System | 2010 |
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Topics: Amiodarone; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Practice Guidelines as Topic; Treatment Outcome | 2010 |
Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Humans; Stroke | 2010 |
Dronedarone: an emerging therapy for atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Approval; Heart Rate; Heart Ventricles; Humans; Secondary Prevention; Treatment Outcome | 2010 |
[Ionic mechanisms of action of class III antiarrhythmic drugs].
Topics: Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Dronedarone; Electric Impedance; Electrocardiography; Heart Atria; Heart Rate; Heart Ventricles; Humans; Ion Channels; Long QT Syndrome; Mutation; Myocytes, Cardiac; Pyrrolidines; Rabbits; Rats | 2010 |
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Fibrinolytic Agents; Humans; Pyridines; Risk Factors; Stroke | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Contraindications; Dronedarone; Drug Approval; Humans; Product Surveillance, Postmarketing; Stroke Volume | 2010 |
Dronedarone: a new antiarrhythmic agent.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Dronedarone; Female; Humans; Male | 2010 |
Dronedarone: an alternative to amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Dronedarone; Drug Interactions; Humans | 2010 |
Dronedarone and vitamin K antagonists: a review of drug-drug interactions.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interactions; Drug Therapy, Combination; Humans; Vitamin K; Warfarin | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dronedarone; Humans; Middle Aged; Randomized Controlled Trials as Topic | 2010 |
Dronedarone for atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
A new agent for atrial fibrillation: electrophysiological properties of dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Electrophysiologic Techniques, Cardiac; Humans | 2010 |
A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Controlled Clinical Trials as Topic; Dronedarone; Heart Failure; Humans; Risk Factors; Secondary Prevention | 2010 |
[Dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Catheter Ablation; Combined Modality Therapy; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Humans; Practice Guidelines as Topic; Premedication; Randomized Controlled Trials as Topic | 2010 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Aged; Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Electrocardiography; Heart Atria; Heart Failure; Heart Ventricles; Humans; Piperazines; Potassium Channels; Pyrrolidines; Ranolazine; Sodium Channels; Stroke | 2010 |
[Novel targets in the treatment of patients with atrial fibrillation: from elimination of symptoms to improvement of clinical outcomes].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic; Dronedarone; Electrocardiography; Heart Rate; Hospitalization; Humans; Monitoring, Physiologic; Practice Patterns, Physicians'; Secondary Prevention; Thromboembolism; Treatment Outcome | 2010 |
Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Disease Models, Animal; Dronedarone; Female; Heart Rate; Humans; Male | 2011 |
Advances in the treatment of atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Dronedarone; Drug Therapy, Combination; Heart Conduction System; Humans; Pyrrolidines; Treatment Outcome | 2010 |
The pharmaceutical pipeline for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome | 2011 |
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Randomized Controlled Trials as Topic; Sotalol; Treatment Outcome | 2011 |
Sinus rhythm restoration and treatment success: insight from recent clinical trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic; Dronedarone; Electric Countershock; Evidence-Based Medicine; Female; Heart Conduction System; Heart Rate; Humans; Male; Recurrence; Treatment Outcome | 2011 |
Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Hospitalization; Humans | 2011 |
Antiarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Pyrrolidines; Stroke; Treatment Outcome | 2011 |
Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Heart Rate; Humans; Sinoatrial Node | 2012 |
Dronedarone for the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans; Treatment Outcome | 2011 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dronedarone; Drug Interactions; Heart Rate; Humans; Recurrence; Treatment Outcome | 2011 |
[The research practice of anti-arrhythmic agents targeting on potassium ion channel].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Humans; Hydantoins; Imidazolidines; Molecular Structure; Piperazines; Potassium Channel Blockers; Potassium Channels | 2011 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Finland; Humans; Patient Selection; Practice Guidelines as Topic; Pyrrolidines | 2011 |
[The role of dronedarone in the contemporary atrial fibrillation treatment].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2011 |
Atrial fibrillation: epidemiology, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Dronedarone; Electric Countershock; Heart Rate; Humans; Prognosis; Quality of Life; Risk Factors; Thromboembolism | 2011 |
[Amiodarone and thyroid function].
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Thyroid Gland; Treatment Outcome | 2011 |
Dronedarone for atrial fibrillation therapy.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Half-Life; Heart Rate; Humans; Time Factors | 2011 |
Update on the management of atrial fibrillation: anticoagulation and medical therapy.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Drug Approval; Evidence-Based Medicine; Factor Xa Inhibitors; Female; Humans; Infusions, Intravenous; Male; Practice Guidelines as Topic; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2011 |
Dronedarone: an overview.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dronedarone; Heart Rate; Hospitalization; Humans; Treatment Outcome | 2012 |
Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Analysis; Dronedarone; Drug Costs; Humans; Quality-Adjusted Life Years; Technology Assessment, Biomedical; United Kingdom | 2012 |
Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Incidence; Ischemic Attack, Transient; Models, Statistical; Randomized Controlled Trials as Topic; Stroke | 2011 |
The management of patients with atrial fibrillation and dronedarone's place in therapy.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dronedarone; Heart Rate; Humans; Practice Guidelines as Topic; Risk Factors; Sex Factors | 2011 |
[Amiodarone and thyroid dysfunction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hypothyroidism; Iodine; Thyroid Gland; Thyrotoxicosis | 2012 |
Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Female; Heart Failure; Humans; Liver; Male; Multicenter Studies as Topic | 2012 |
Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Brain Ischemia; Dronedarone; Humans; Myocardial Ischemia; Reperfusion Injury | 2012 |
[Dronedarone: a real innovation or a mere second-best choice? How to find the way among guidelines, regulatory agencies and daily clinical practice].
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Liver Failure, Acute; Liver Function Tests; Practice Guidelines as Topic | 2012 |
Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Pharmacology of myocardial calcium-handling.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium; Calcium Channel Blockers; Cardiomegaly; Cardiotonic Agents; Digitalis Glycosides; Dronedarone; Electrocardiography; Heart Failure; Humans; Ion Channels; Myocardial Contraction; Piperazines; Ranolazine; Signal Transduction; Tachycardia | 2012 |
Atrial fibrillation: new drugs, devices, and procedures.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dronedarone; Equipment and Supplies; Humans; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Novel anti-arrhythmic medications in the treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Dronedarone; Forecasting; Heart Failure; Humans; Phenethylamines; Piperazines; Pyrrolidines; Ranolazine; Sulfonamides; Technology, Pharmaceutical; Ventricular Dysfunction, Left | 2012 |
Drug safety evaluation of dronedarone in atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Labeling; Hospitalization; Humans; Patient Selection; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2012 |
Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Drug Monitoring; Early Termination of Clinical Trials; Humans; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Heart Failure; Heart Rate; Humans; Risk Assessment | 2013 |
Dronedarone-induced optic neuropathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Male; Optic Nerve Diseases | 2013 |
[Effect of amiodarone on the thyroid function and safety of the therapy--what's new].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Causality; Comorbidity; Dronedarone; Humans; Hyperthyroidism; Hypothyroidism; Smoking; Thyroid Gland; Thyrotoxicosis | 2012 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Piperazines; Pyrrolidines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Hospitalization; Humans; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2014 |
The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Half-Life; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Risk; Secondary Prevention | 2014 |
[Every sixth patient in amiodarone treatment develops thyrotoxicosis or hypothyreosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Drug Prescriptions; Humans; Hypothyroidism; Risk Factors; Thyrotoxicosis | 2014 |
Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Dronedarone; Drug Costs; Humans; Risk Assessment; Treatment Outcome | 2014 |
Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Disease Management; Dronedarone; Fibrinolytic Agents; Hemophilia A; Hemorrhage; Humans; Male; Thrombophilia | 2015 |
Dronedarone and renal impairment: evaluation of Spanish postmarketing reports and review of literature.
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Dronedarone; Humans; Pharmacovigilance; Renal Insufficiency; Spain; Time Factors | 2015 |
New anthyarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Pyrrolidines; Ranolazine | 2015 |
Amiodarone and dronedarone: An update.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interactions; Heart Conduction System; Heart Rate; Humans; Patient Selection; Risk Factors; Treatment Outcome | 2016 |
Dronedarone: Basic Pharmacology and Clinical Use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2016 |
Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic; Regression Analysis | 2017 |
Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Clinical Trials as Topic; Dronedarone; Drug Therapy, Combination; Humans; Male; Ranolazine; Recurrence; Treatment Outcome | 2017 |
Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation.
Topics: Age Factors; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Patient Selection; Randomized Controlled Trials as Topic; Risk Factors | 2017 |
Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Network Meta-Analysis; Sotalol | 2023 |
36 trial(s) available for amiodarone and dronedarone
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Blood Pressure; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Drug Interactions; Echocardiography; Electrocardiography; Genotype; Heart Rate; Hemodynamics; Humans; Male; Mass Spectrometry; Metoprolol; Polymorphism, Genetic | 2004 |
Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions.
Topics: Administration, Oral; Adult; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Circadian Rhythm; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Electrocardiography, Ambulatory; Heart Conduction System; Heart Rate; Heart Ventricles; Humans; Linear Models; Male; Reference Values | 2006 |
Effect of dronedarone on renal function in healthy subjects.
Topics: Adult; Amiodarone; Cross-Over Studies; Double-Blind Method; Dronedarone; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Electrocardiography; Female; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Secondary Prevention; Time Factors | 2007 |
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Hospitalization; Humans; Internationality; Placebo Effect; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2008 |
Increased mortality after dronedarone therapy for severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Dronedarone; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Treatment Failure; Ventricular Dysfunction, Left | 2008 |
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Double-Blind Method; Dronedarone; Exercise; Female; Heart Rate; Humans; Internationality; Male; Middle Aged; Physical Endurance; Time Factors; Treatment Outcome; Ventricular Function | 2008 |
[Efficacy of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Results of the EURIDIS and ADONIS].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Stroke Volume; Time Factors; Treatment Outcome | 2008 |
[Efficacy of dronedarone in cardiac failure due to severe left ventricular systolic dysfunction. Results of the ANDROMEDA].
Topics: Amiodarone; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Follow-Up Studies; Heart Failure; Humans; Prospective Studies; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; Creatinine; Double-Blind Method; Dronedarone; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors; Secondary Prevention; Treatment Outcome | 2009 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Electrocardiography; Endpoint Determination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Risk Assessment; Thyroid Diseases | 2010 |
Dronedarone in patients with congestive heart failure: insights from ATHENA.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Creatinine; Dronedarone; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Treatment Outcome; Ventricular Dysfunction, Left | 2010 |
Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure.
Topics: Amiodarone; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Exercise; Exercise Test; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Placebos; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Left | 2010 |
Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male; Middle Aged; Treatment Outcome | 2011 |
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cause of Death; Combined Modality Therapy; Double-Blind Method; Dronedarone; Electric Countershock; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Risk; Secondary Prevention; Signal Processing, Computer-Assisted; Stroke; Utilization Review | 2011 |
Post-ATHENA and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Heart Failure; Heart Ventricles; Hospitalization; Humans; Risk Assessment; Secondary Prevention; Treatment Outcome | 2011 |
Comment: worsening heart failure in the setting of dronedarone initiation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Heart Failure; Humans; Male; Middle Aged; Treatment Failure | 2011 |
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Dronedarone; Female; Follow-Up Studies; Hospitalization; Humans; Incidence; Kaplan-Meier Estimate; Length of Stay; Male; Secondary Prevention | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Diseases; Chronic Disease; Digoxin; Double-Blind Method; Dronedarone; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Risk Factors; Stroke | 2011 |
Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diagnostic Tests, Routine; Dronedarone; Drug Costs; Europe; Female; Hospital Costs; Hospitalization; Humans; Male; Models, Economic; Office Visits; Quality-Adjusted Life Years; Stroke; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial.
Topics: Aged; Amiodarone; Atrial Fibrillation; Cost-Benefit Analysis; Dronedarone; Drug Costs; Female; Follow-Up Studies; Humans; Male; Ontario; Quebec; Retrospective Studies | 2013 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedarone; Electric Countershock; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Propafenone; Recurrence; Time Factors | 2014 |
Interaction between digoxin and dronedarone in the PALLAS trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents; Cause of Death; Digoxin; Double-Blind Method; Dronedarone; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Topics: Adolescent; Adult; Aged; Amiodarone; Area Under Curve; Biotransformation; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Double-Blind Method; Dronedarone; Drug Interactions; Humans; Intestinal Absorption; Male; Middle Aged; Models, Biological; Polymorphism, Single Nucleotide; Reproducibility of Results; Secondary Metabolism; Ticlopidine; Tissue Distribution; Young Adult | 2015 |
A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Monitoring, Physiologic; Pacemaker, Artificial; Reference Values; Risk Assessment; Time Factors; Treatment Outcome | 2015 |
One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Longitudinal Studies; Male; Middle Aged; Patient Safety; Patient Satisfaction; Prevalence; Prospective Studies; Quality of Life; Risk Assessment; Treatment Outcome | 2015 |
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Pacemaker, Artificial; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2015 |
Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiac Output; Diastole; Dogs; Dronedarone; Electrocardiography; Female; Heart; Heart Ventricles; Hemodynamics; Injections, Intravenous; Male | 2016 |
Prophylactic amiodarone vs dronedarone for prevention of perioperative arrhythmias in offpump coronary artery bypass grafting: A pilot randomized controlled trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Artery Bypass; Dronedarone; Humans; Male; Perioperative Care; Pilot Projects; Postoperative Complications | 2017 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Female; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Treatment Outcome | 2020 |
Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Humans; Infant, Newborn; Male | 2022 |
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Kidney; Treatment Outcome | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Humans | 2022 |
Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Treatment Outcome | 2022 |
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Hospitalization; Humans | 2023 |
267 other study(ies) available for amiodarone and dronedarone
| Article | Year |
|---|---|
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship, Drug; Drug Stability; Epoxide Hydrolases; Esterification; Hepatocytes; Humans; Male; Mice; Microsomes, Liver; Myocardial Infarction; Myocytes, Cardiac; Rats, Sprague-Dawley; Rats, Wistar | 2019 |
SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs.
Topics: Administration, Oral; Adrenergic Antagonists; Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Benzofurans; Blood Pressure; Dogs; Dronedarone; Electrocardiography; Female; Heart Rate; Injections, Intravenous; Isoproterenol; Male | 1995 |
SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Dogs; Dronedarone; Electric Stimulation; Electrocardiography; Electrodes, Implanted; Electrophysiology; Female; Injections, Intravenous; Male; Structure-Activity Relationship | 1995 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Death, Sudden, Cardiac; Disease Models, Animal; Dronedarone; Female; Lidocaine; Male; Myocardial Ischemia; Sotalol; Stereoisomerism; Swine; Tachycardia, Ventricular; Ventricular Fibrillation | 1995 |
SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Chi-Square Distribution; Disease Models, Animal; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Heart Block; Heart Rate; Injections, Intravenous; Lidocaine; Myocardial Reperfusion Injury; Random Allocation; Rats; Sotalol; Ventricular Fibrillation | 1995 |
Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Binding, Competitive; Dose-Response Relationship, Drug; Down-Regulation; Dronedarone; Enzyme Inhibitors; Heart; Iodocyanopindolol; Linear Models; Male; Myocardium; Pindolol; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Thyroid Hormones | 1995 |
Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias.
Topics: Action Potentials; Administration, Oral; Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Dogs; Dronedarone; Electrocardiography; Female; Heart Ventricles; Injections, Intravenous; Male; Propanolamines; Time Factors; Torsades de Pointes; Ventricular Function | 1999 |
Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Drug Interactions; Electrophysiology; Female; Heart; Ion Transport; Male; Myocardium; Papillary Muscles; Rabbits; Sinoatrial Node; Sodium Channels; Structure-Activity Relationship; Thyroxine | 1999 |
Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats.
Topics: Action Potentials; Age Factors; Amiodarone; Animals; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Dronedarone; Heart; In Vitro Techniques; Ion Transport; Ligation; Male; Myocardial Infarction; Potassium; Rats; Rats, Wistar; Time Factors | 2000 |
Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells.
Topics: Acetylcholine; Amiodarone; Animals; Dose-Response Relationship, Drug; Dronedarone; Guanosine 5'-O-(3-Thiotriphosphate); Membrane Potentials; Patch-Clamp Techniques; Potassium Channels; Rabbits; Receptor, Muscarinic M2; Receptors, Muscarinic; Sinoatrial Node | 2000 |
Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
Topics: Adrenergic Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Dogs; Dronedarone; Echocardiography; Female; Hemodynamics; Male; Myocardial Infarction; Sympathetic Nervous System | 2000 |
Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cell Separation; Dronedarone; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Heart Atria; In Vitro Techniques; Myocardium; Patch-Clamp Techniques; Potassium Channels; Receptors, Muscarinic; Stimulation, Chemical | 2000 |
Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone.
Topics: Action Potentials; Amiodarone; Animals; Dogs; Dronedarone; Electric Stimulation; Electrocardiography; Electrophysiology; Female; Heart Ventricles; In Vitro Techniques; Male; Papillary Muscles; Purkinje Fibers; Vasodilator Agents; Ventricular Function | 2001 |
Beneficial effects of amiodarone and dronedarone (SR 33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters asssessed during reperfusion in isolated rat hearts.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Dose-Response Relationship, Drug; Dronedarone; Female; In Vitro Techniques; Myocardial Ischemia; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Tachycardia, Ventricular | 2001 |
Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
Topics: Action Potentials; Administration, Oral; Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Catheterization; Disease Models, Animal; Dogs; Dronedarone; Electrocardiography; Electrophysiologic Techniques, Cardiac; Epinephrine; Female; Heart Block; Hemodynamics; Long QT Syndrome; Male; Myocardium; Organ Size; Torsades de Pointes; Vasoconstrictor Agents; Wakefulness | 2001 |
Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Function; Dronedarone; Drug Administration Schedule; Female; In Vitro Techniques; Male; Myocardium; Rabbits | 2002 |
Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart.
Topics: Amiodarone; Animals; Dronedarone; Heart; In Vitro Techniques; Male; Myocardial Ischemia; Rats; Rats, Wistar; Thyroid Hormones | 2002 |
Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Depression, Chemical; Dronedarone; Electrocardiography; Heart Rate; Male; Models, Animal; Myocytes, Cardiac; Rabbits; Sarcolemma; Sodium-Potassium-Exchanging ATPase; Thyroid Gland; Thyroidectomy | 2003 |
Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Enzyme Activation; Heart Rate; In Vitro Techniques; Iodide Peroxidase; Liver; Male; Rats; Rats, Wistar; Thyroid Hormone Receptors alpha; Triiodothyronine | 2003 |
Electrophysiologic characterization of dronedarone in guinea pig ventricular cells.
Topics: Action Potentials; Amiodarone; Animals; Calcium Channels, L-Type; Dose-Response Relationship, Drug; Dronedarone; Electrophysiology; Guinea Pigs; Heart Ventricles; In Vitro Techniques; Male; Myocytes, Cardiac; Papillary Muscles; Ventricular Function | 2003 |
Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.
Topics: Adult; Aged; Amiodarone; Atrial Function; Cells, Cultured; Dronedarone; Humans; Ion Channel Gating; Membrane Potentials; Middle Aged; Myocytes, Cardiac; Sodium Channels | 2003 |
Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.
Topics: Action Potentials; Amiodarone; Animals; Cation Transport Proteins; Delayed Rectifier Potassium Channels; Dronedarone; Ether-A-Go-Go Potassium Channels; Female; Humans; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Xenopus laevis | 2003 |
Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Cell Survival; Dronedarone; Iodine Radioisotopes; Macrophages, Alveolar; Microscopy, Electron; Pulmonary Surfactant-Associated Protein A; Rabbits; Structure-Activity Relationship; Trachea | 2004 |
Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart.
Topics: Amiodarone; Animals; Coronary Vessels; Dose-Response Relationship, Drug; Dronedarone; Guinea Pigs; Heart; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Vasodilation | 2004 |
High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Topics: Amino Acid Substitution; Amiodarone; Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Dronedarone; Drug Resistance; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Ion Channel Gating; Kidney; Membrane Potentials; Mutagenesis, Site-Directed; Potassium Channels, Voltage-Gated; Recombinant Proteins; Structure-Activity Relationship | 2004 |
Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1.
Topics: Adaptation, Physiological; Amiodarone; Animals; Calcium-Transporting ATPases; Dronedarone; Eating; Glycogen; Heart; Heart Rate; Hypothyroidism; In Vitro Techniques; Isomerism; L-Lactate Dehydrogenase; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Myosins; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Thyroid Hormone Receptors alpha; Thyroid Hormones; Weight Gain | 2005 |
This DAFNE is definitely not that DAFNE.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Electric Countershock; Humans; Terminology as Topic | 2005 |
Amiodarone inhibits thyroidal iodide transport in vitro by a cyclic adenosine 5'-monophosphate- and iodine-independent mechanism.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Biological Transport; Cells, Cultured; Cyclic AMP; Dronedarone; Electrolytes; Iodides; Iodine; RNA, Messenger; Swine; Symporters; Thyroid Gland; Thyrotropin | 2006 |
Dronedarone: a new antiarrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availability; Clinical Trials as Topic; Dronedarone; Humans; Metabolic Clearance Rate; Treatment Outcome | 2006 |
[Dronedarone establishes and maintains control of sinus rhythm].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2006 |
Comment on dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans; Outcome Assessment, Health Care; Patient Selection; Treatment Outcome | 2006 |
Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight.
Topics: Amiodarone; Animals; Dronedarone; Drug Synergism; Eating; Rats; Rats, Wistar; Thyroid Hormone Receptors alpha; Thyroxine; Weight Loss | 2007 |
Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dronedarone; Electrocardiography, Ambulatory; Epinephrine; Female; Myocardial Infarction; Norepinephrine; Radioimmunoassay; Random Allocation; Rats; Rats, Wistar; Tachycardia, Ventricular; Telemetry; Thyroid Hormones; Ventricular Fibrillation | 2007 |
Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Dronedarone; Gene Expression Regulation; Heart; In Situ Hybridization; Male; Rats; Rats, Wistar; RNA, Messenger; Thyroid Hormone Receptors alpha; Thyroid Hormone Receptors beta; Thyroxine; Triiodothyronine | 2007 |
Maintaining sinus rhythm--making treatment better than the disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Failure; Humans; Secondary Prevention | 2007 |
Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Electrophysiology; In Vitro Techniques; Isoproterenol; Male; Microelectrodes; Rabbits; Sinoatrial Node; Tachycardia, Supraventricular | 2007 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hyperthyroidism; Proportional Hazards Models; Secondary Prevention | 2007 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Quality of Life; Secondary Prevention | 2007 |
Is dronedarone effective for the prevention of recurrent atrial fibrillation?
Topics: Amiodarone; Atrial Fibrillation; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Multicenter Studies as Topic; Probability; Prognosis; Randomized Controlled Trials as Topic; Secondary Prevention; Sensitivity and Specificity; Severity of Illness Index; Survival Rate; Treatment Outcome | 2008 |
In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle.
Topics: Action Potentials; Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Dogs; Dronedarone; Endocardium; Heart Ventricles; In Vitro Techniques; Male; Myocardium; Pericardium; Sotalol; Ventricular Function, Left | 2007 |
Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Dronedarone; Guinea Pigs; Heart Ventricles; Inhibitory Concentration 50; Myocytes, Cardiac; Patch-Clamp Techniques; Sodium-Calcium Exchanger; Trypsin | 2008 |
New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Dronedarone; Humans; Pyrrolidines | 2008 |
Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiotonic Agents; Clinical Trials as Topic; Dronedarone; Heart Failure; Humans | 2008 |
[Current pharmacological management of atrial fibrillation management by practice cardiologists - news from congress in Munich].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Cardiology; Congresses as Topic; Dronedarone; Europe; Humans; Practice Guidelines as Topic; Secondary Prevention | 2008 |
Alternatives to amiodarone: search for the Holy Grail.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Combined Modality Therapy; Dose-Response Relationship, Drug; Dronedarone; Humans; Pacemaker, Artificial; Phenethylamines; Sulfonamides | 2009 |
Trial watch: novel antiarrhythmic agent shows promise in Phase III trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dronedarone; Humans | 2009 |
Dronedarone for atrial fibrillation--an odyssey.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Dronedarone; Drug Approval; Humans; Molecular Structure; Stroke Volume; United States; United States Food and Drug Administration | 2009 |
New pharmacological options for patients with atrial fibrillation: the ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Endpoint Determination; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Determination of the class III antiarrhythmic drugs dronedarone and amiodarone, and their principal metabolites in plasma and myocardium by high-performance liquid chromatography and UV-detection.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Dronedarone; Humans; Myocardium; Spectrophotometry, Ultraviolet | 2009 |
[How did ATHENA win ANDROMEDA? Results of the ATHENA].
Topics: Amiodarone; Arrhythmias, Cardiac; Dronedarone; Electrocardiography; Heart Rate; Humans; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Hospitalization; Humans | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male; Secondary Prevention; Sex Factors | 2009 |
Dronedarone in atrial fibrillation.
Topics: Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Dronedarone; Heart Rate; Hospitalization; Humans | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Hospitalization; Humans; Secondary Prevention | 2009 |
Dronedarone approved for atrial arrhythmias.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Drug Approval; Drug Labeling; Humans; United States; United States Food and Drug Administration | 2009 |
Amiodarone or dronedarone for atrial fibrillation: too early to know the winner?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Heart Rate; Humans; Treatment Outcome | 2009 |
Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Hospitalization; Humans; Risk Factors | 2009 |
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Female; Humans; International Normalized Ratio; Male; Middle Aged; Multivariate Analysis; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2009 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic | 2009 |
Dronedarone (Multaq) for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Interactions; Humans; United States; United States Food and Drug Administration | 2009 |
Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Humans | 2010 |
Atrial fibrillation. DIONYSOS study comparing dronedarone with amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2010 |
[Comparison of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Indirect meta-analysis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Meta-Analysis as Topic; Treatment Outcome | 2010 |
FDA drug information that never reaches clinicians.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Approval; Drug Labeling; Humans; Information Dissemination; United States; United States Food and Drug Administration | 2010 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electrocardiography; Humans; Meta-Analysis as Topic; Odds Ratio; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
Dronedarone is superior to placebo the case for optimism.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electrocardiography; Humans; Odds Ratio; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
A perspective on DIONYSOS.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic | 2010 |
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Diseases; Clinical Trials as Topic; Dronedarone; Humans | 2010 |
Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Availability; Cytochrome P-450 CYP3A; Dronedarone; Drug Interactions; Food-Drug Interactions; Half-Life; Humans | 2010 |
Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Dronedarone; Electrophysiologic Techniques, Cardiac; Heart Atria; Heart Conduction System; Treatment Outcome | 2010 |
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Controlled Clinical Trials as Topic; Cost Savings; Databases as Topic; Dronedarone; Drug Costs; Female; Hospital Costs; Hospital Mortality; Hospitalization; Humans; Inpatients; Male; Medicare Part B; Models, Economic; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2010 |
Dronedarone: a review of characteristics and clinical data.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Humans | 2010 |
Suppression of ventricular tachycardia with dronedarone: a case report.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Dronedarone; Humans; Male; Secondary Prevention; Tachycardia, Ventricular; Treatment Outcome | 2011 |
Amiodarone and dronedarone: the worker bee and the drone?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Electrophysiologic Techniques, Cardiac; Heart Atria; Heart Conduction System; Humans; Treatment Outcome | 2010 |
Worsening heart failure in the setting of dronedarone initiation.
Topics: Acute Kidney Injury; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Progression; Dronedarone; Heart Failure; Humans; Liver Failure, Acute; Male; Middle Aged | 2010 |
Dronedarone: NICE enough?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Dronedarone; Humans; Practice Guidelines as Topic; Secondary Prevention | 2010 |
Dronedarone: where does it fit in the treatment of atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Therapy, Combination; Humans; Secondary Prevention; Treatment Outcome | 2010 |
Role of dronedarone in atrial fibrillation: more questions than answers.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans | 2010 |
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Dronedarone; Drug Synergism; Drug Therapy, Combination; Piperazines; Ranolazine | 2010 |
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Treatment Outcome | 2010 |
Dronedarone. atrial fibrillation: too many questions about long-term adverse effects.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; European Union; Heart Failure; Heart Rate; Humans | 2010 |
The dronedarone odyssey.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Approval; Europe; Humans; United States | 2010 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Diagnosis, Differential; Dronedarone; Humans; Vitamin K | 2010 |
A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Dronedarone; Humans; Male; Secondary Prevention; Tachycardia, Ventricular; Treatment Outcome | 2011 |
Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Randomized Controlled Trials as Topic | 2010 |
[New antiarrhythmic drugs for treatment of atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Design; Electric Countershock; Humans; Membrane Transport Modulators; Pyrrolidines | 2010 |
Treatment of atrial fibrillation in 2010 and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Prevalence; Quality of Life; United States | 2010 |
Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Drug Therapy, Combination; Humans; Sotalol | 2010 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Topics: Algorithms; Amiodarone; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Dronedarone; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Recurrence; Treatment Outcome | 2011 |
Effect of dronedarone on Na+, Ca2+ and HCN channels.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium Channels; CHO Cells; Cricetinae; Cricetulus; Cyclic Nucleotide-Gated Cation Channels; Dronedarone; Guinea Pigs; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Inhibitory Concentration 50; Male; Membrane Potentials; Muscle Proteins; Patch-Clamp Techniques; Potassium Channels; Sodium Channels; Swine | 2011 |
An important indirect drug interaction between dronedarone and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function.
Topics: Amiodarone; Anticoagulants; Dronedarone; Drug Interactions; Gastrointestinal Tract; Humans; Warfarin | 2011 |
Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT1A receptors: mediation by thyroid hormone α receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amiodarone; Animals; Antidepressive Agents; Body Weight; Dose-Response Relationship, Drug; Dronedarone; Drug Evaluation, Preclinical; Environment; Feeding Behavior; Female; Hindlimb Suspension; Hypothermia; Male; Mice; Mice, Inbred BALB C; Receptor, Serotonin, 5-HT1A; Receptors, Presynaptic; Serotonin Antagonists; Serotonin Receptor Agonists; Sex Characteristics; Swimming; Thyroid Hormone Receptors alpha; Triiodothyronine | 2011 |
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Flecainide; Humans; Propafenone; Sotalol; Treatment Outcome | 2011 |
Dronedarone for atrial fibrillation: How does it compare with amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Humans; Prescription Fees | 2011 |
In brief: FDA warning on dronedarone (Multaq).
Topics: Amiodarone; Anti-Arrhythmia Agents; Chemical and Drug Induced Liver Injury; Dronedarone; Drug Labeling; Humans; United States; United States Food and Drug Administration | 2011 |
What's new in...atrial fibrillation. Is dronedarone more effective than amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2011 |
[Treatment of atrial fibrillation: when to use drugs or to perform ablation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic; Dronedarone; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Recurrence; Time Factors; Treatment Outcome | 2010 |
Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor.
Topics: Amiodarone; Animals; Dronedarone; Drug Synergism; Heart; In Vitro Techniques; Male; Myocardial Contraction; Rats; Rats, Wistar; Reperfusion Injury; Thyroid Hormone Receptors alpha; Thyroxine; Triiodothyronine | 2011 |
The impact of dronedarone on lone atrial fibrillation: perhaps not such a "benign" arrhythmia?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2011 |
Reduction of myocardial infarct size by dronedarone in pigs--a pleiotropic action?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Calcium; Cardiotonic Agents; Coronary Circulation; Dronedarone; Heart Rate; Myocardial Infarction; Myocardial Reperfusion Injury; Swine; Swine, Miniature | 2011 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Heart Rate; Humans; Stroke | 2011 |
[Perspectives and recommendations for the anti-arrhythmic treatment of atrial fibrillation: focus on dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2011 |
Hospitalization: a relevant endpoint in atrial fibrillation management?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male | 2011 |
Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Docetaxel; Dronedarone; Drug Administration Schedule; Drug Overdose; Fatal Outcome; Humans; Male; Mucositis; Prostatic Neoplasms; Taxoids | 2011 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Electrocardiography; Heart Rate; Humans; Male; Outpatients; Stroke; Treatment Outcome | 2011 |
Elevated international normalized ratio associated with use of dronedarone and warfarin.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Dose-Response Relationship, Drug; Dronedarone; Drug Interactions; Drug Monitoring; Female; Humans; International Normalized Ratio; Warfarin | 2011 |
Acute liver failure associated with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Dronedarone; Female; Humans; Liver; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Treatment Outcome | 2011 |
Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype.
Topics: Amiodarone; Androstenes; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Cholesterol; Dose-Response Relationship, Drug; Dronedarone; Endosomes; Humans; Lysophospholipids; Molecular Structure; Monoglycerides; Niemann-Pick Diseases; Nocodazole | 2011 |
Reduction of cerebral infarct size by dronedarone.
Topics: Amiodarone; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Dronedarone; Heart Rate; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Magnetic Resonance Imaging; Male; Neuroprotective Agents; Rats; Rats, Wistar; Treatment Outcome | 2011 |
Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Dronedarone; Humans; Male; Tandem Mass Spectrometry | 2011 |
Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Contraindications; Databases, Factual; Dronedarone; Drug Interactions; Drug Prescriptions; Drug Utilization Review; Female; Humans; Insurance Claim Review; Male; Middle Aged; United States; Young Adult | 2011 |
Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Electrocardiography; Electrophysiologic Techniques, Cardiac; Female; Heart Ventricles; In Vitro Techniques; Long QT Syndrome; Perfusion; Rabbits; Refractory Period, Electrophysiological; Sotalol; Torsades de Pointes; Ventricular Function | 2012 |
Dronedarone: liver damage and cardiac disorders. Negative harm-benefit balance.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chemical and Drug Induced Liver Injury; Dronedarone; Heart Diseases; Humans; Renal Insufficiency | 2011 |
Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration.
Topics: Amiodarone; Animals; Chemical and Drug Induced Liver Injury; Dronedarone; Hydrogen Peroxide; Liver; Male; Mitochondria, Liver; Mitochondrial Membranes; Oxidative Stress; Phospholipids; Rats; Rats, Wistar | 2011 |
Dronedarone in atrial fibrillation--Jekyll and Hyde?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2011 |
Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.
Topics: Acute Coronary Syndrome; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blotting, Western; Cardiac Pacing, Artificial; Cell Line; Coronary Circulation; Dronedarone; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Microcirculation; Myocytes, Cardiac; NADPH Oxidases; Oxidative Stress; Phosphorylation; Protein Kinase C; Real-Time Polymerase Chain Reaction; Swine | 2012 |
[Who protects physicians and patients from guidelines?].
Topics: Adenosine; Aged; Amiodarone; Anti-Arrhythmia Agents; Consensus Development Conferences as Topic; Dronedarone; Drug Approval; Early Termination of Clinical Trials; Evidence-Based Medicine; Germany; Guideline Adherence; Heart Diseases; Humans; Malpractice; National Health Programs; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor | 2011 |
Dronedarone: a new hope for stroke prevention in atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Risk Factors; Stroke | 2011 |
Safety of dronedarone (Multaq).
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans | 2011 |
Dronedarone trial stopped due to excess mortality.
Topics: Amiodarone; Atrial Fibrillation; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dronedarone; Early Termination of Clinical Trials; Humans | 2011 |
[Atrial fibrillation. PALLAS study: when dronedarone becomes a risk].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Contraindications; Dronedarone; Early Termination of Clinical Trials; Endpoint Determination; Humans; Patient Admission; Risk Factors; Survival Rate | 2011 |
Chronic oral amiodarone but not dronedarone therapy increases ventricular defibrillation threshold during acute myocardial ischemia in a closed-chest animal model.
Topics: Acute Disease; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Coronary Occlusion; Defibrillators, Implantable; Disease Models, Animal; Dronedarone; Female; Male; Myocardial Ischemia; Swine; Ventricular Fibrillation | 2012 |
Second chance for dronedarone after recent setback?
Topics: Acetanilides; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Contraindications; Dronedarone; Drug Approval; Drug Therapy, Combination; Electrocardiography; Europe; Humans; Piperazines; Ranolazine; Sodium Channel Blockers; Survival Analysis; United States | 2012 |
Who protects physicians and patients from guidelines?
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Drug Approval; Guideline Adherence; Humans; Patient Safety; Practice Guidelines as Topic; Practice Patterns, Physicians'; Purinergic P2Y Receptor Antagonists; Safety-Based Drug Withdrawals; Ticagrelor | 2012 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Fatal lung toxic effects related to dronedarone use.
Topics: Aged; Aged, 80 and over; Amiodarone; Dronedarone; Fatal Outcome; Female; Humans; Lung Diseases; Male | 2012 |
Dronedarone use and fatal lung toxic effects?
Topics: Amiodarone; Dronedarone; Female; Humans; Lung Diseases; Male | 2012 |
Efficacy and safety profile of dronedarone in clinical practice. Preliminary results of the Magdeburg Dronedarone Registry.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Cohort Studies; Dronedarone; Female; Follow-Up Studies; Gastrointestinal Diseases; Germany; Humans; Male; Middle Aged; Prospective Studies; Registries; Treatment Outcome | 2012 |
In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.
Topics: Amiodarone; Calcium; Chagas Disease; Dronedarone; Membrane Potential, Mitochondrial; Trypanosoma cruzi | 2012 |
[The PALLAS study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Intervals; Dronedarone; Humans; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2012 |
[Between guidelines and regulatory decisions: the odyssey of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug and Narcotic Control; Evidence-Based Medicine; Heart Rate; Humans; Liver Failure, Acute; Practice Guidelines as Topic; Risk Factors; Treatment Outcome | 2012 |
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiovascular Diseases; Cost-Benefit Analysis; Dronedarone; Europe; Health Status; Humans; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sex Factors; Survival Analysis | 2013 |
[Rhythm---control in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Dronedarone; Drug Approval; Early Termination of Clinical Trials; Electrocardiography; Germany; Humans; Randomized Controlled Trials as Topic; Survival Rate | 2012 |
Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Heart Arrest; Humans; Retrospective Studies; Torsades de Pointes; United States; United States Food and Drug Administration | 2012 |
Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; Follow-Up Studies; Gastrointestinal Diseases; Germany; Humans; Male; Middle Aged; Prospective Studies; Registries; Treatment Outcome | 2013 |
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
Topics: Amiodarone; Animals; Atrial Fibrillation; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dronedarone; Ion Channel Gating; Membrane Potentials; Myocardium; Oocytes; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Tandem Pore Domain; Transfection; Xenopus laevis | 2012 |
A 73-year-old man with interstitial lung disease due to dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Lung; Lung Diseases, Interstitial; Male | 2012 |
Possible proarrhythmia with dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Humans; Male; Middle Aged; Tachycardia, Ventricular; Treatment Outcome | 2013 |
Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatinine; Cystatin C; Dronedarone; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Protein Stability; Reproducibility of Results; Up-Regulation | 2013 |
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Guideline Adherence; Health Care Surveys; Healthcare Disparities; Humans; Italy; Marketing of Health Services; Practice Guidelines as Topic; Practice Patterns, Physicians'; Sweden; Time Factors | 2013 |
Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.
Topics: Acetanilides; Amiodarone; Animals; Atrial Fibrillation; Chromatography, High Pressure Liquid; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Electrocardiography; Hemodynamics; Piperazines; Ranolazine; Swine; Tachycardia, Ventricular | 2013 |
[Update 2012: new European guidelines for atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Germany; Humans; Long-Term Care; Practice Guidelines as Topic; Risk Assessment; Stroke; Thromboembolism; Vitamin K | 2012 |
Dronedarone reduces arterial thrombus formation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Aorta; Dronedarone; Lipoproteins; Mice; Mice, Inbred C57BL; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Thromboplastin; Thrombosis; Whole Blood Coagulation Time | 2012 |
Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting database.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Dronedarone; Female; Humans; Italy; Male; Middle Aged; Pharmacovigilance; Risk Factors | 2013 |
[New antiarrhythmic drugs for the treatment of atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Pyrrolidines | 2012 |
Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone.
Topics: Adenosine Triphosphate; Amiodarone; Animals; Anti-Arrhythmia Agents; Base Sequence; Caspase 3; Caspase 7; Cell Line, Tumor; Cytochromes c; DNA Primers; Dronedarone; Humans; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction | 2013 |
Dronedarone: is it time to turn it down?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Humans; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Dronedarone; Humans; Male; Tachycardia, Ventricular | 2012 |
Effects of dronedarone and amiodarone on atrial fibrillatory rate in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Female; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2013 |
[Febrile maculopapular eruption due to dronedarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Diagnosis, Differential; Dronedarone; Drug Eruptions; Fever; Humans; Male; Skin | 2012 |
Torsade de pointes due to dronedarone: déjà vu?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Humans | 2012 |
Effects of dronedarone started rapidly after amiodarone discontinuation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Dronedarone; Drug Substitution; Female; Half-Life; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
Different effects of dronedarone and amiodarone on pulmonary vein electrophysiology, mechanical properties and H2O2-induced arrhythmogenicity.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Electrophysiological Phenomena; Hydrogen Peroxide; In Vitro Techniques; Oxidative Stress; Pulmonary Veins; Rabbits | 2013 |
Usefulness of dronedarone in patients with atrial arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2013 |
Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dronedarone; Electrocardiography; Europe; Guideline Adherence; Health Care Surveys; Humans; Patient Selection; Practice Guidelines as Topic; Practice Patterns, Physicians'; Predictive Value of Tests; Recurrence; Treatment Outcome | 2013 |
Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.
Topics: Amiodarone; Animals; Calcium-Binding Proteins; Dronedarone; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Ischemia; Myosins; Organ Size; Protein Isoforms; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Stroke Volume; Thyroid Hormone Receptors alpha; Thyroid Hormones; Ventricular Function, Left | 2013 |
Dronedarone and Captisol-enabled amiodarone in an experimental cardiac arrest.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiopulmonary Resuscitation; Disease Models, Animal; Dronedarone; Electric Countershock; Heart Arrest; Heart Rate; Swine; Ventricular Fibrillation | 2013 |
Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Approval; Humans; National Institutes of Health (U.S.); Practice Guidelines as Topic; United States | 2013 |
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Female; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol | 2013 |
Dronedarone's inhibition of If current is the primary mechanism responsible for its bradycardic effect.
Topics: Amiodarone; Analysis of Variance; Animals; Arterial Pressure; Benzazepines; Blood Pressure; Bradycardia; Diltiazem; Dronedarone; Isoproterenol; Ivabradine; Myocardial Contraction; Swine | 2013 |
Which patient is most likely to benefit from dronedarone? Analysis from the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Atria; Humans; Male; Middle Aged; Organ Size; Recurrence; Registries | 2013 |
Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy.
Topics: Acute Kidney Injury; Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Cardiovascular Diseases; Dehydration; Diarrhea; Dronedarone; Humans; Hypotension; Male; Pharmacovigilance; Polypharmacy; Renal Dialysis | 2013 |
The dronedarone shared-care clinical model and database: a coordinated paradigm to optimize management of evolving clinical recommendations.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Dronedarone; Female; Guideline Adherence; Humans; Liver Function Tests; Male; Middle Aged; Northern Ireland; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Registries | 2013 |
Severe toxic hepatitis associated with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury, Chronic; Dronedarone; Female; Humans; Severity of Illness Index | 2013 |
Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Ambulatory; Fatigue; Humans; Long QT Syndrome; Male; Ventricular Premature Complexes | 2013 |
Stability-indicating UPLC method for determining related substances and degradants in dronedarone.
Topics: Amiodarone; Chromatography, High Pressure Liquid; Dronedarone; Drug Stability; Limit of Detection; Linear Models; Reproducibility of Results | 2014 |
Exercise intolerance in patients on dronedarone. What is the underlying mechanism?
Topics: Amiodarone; Arrhythmias, Cardiac; Dronedarone; Dyspnea; Exercise Tolerance; Female; Humans; Male; Middle Aged | 2013 |
Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Electrocardiography; Heart Rate; Heart Ventricles; Ivabradine; Male; Swine; Ventricular Function, Left | 2013 |
The funny and not-so-funny effects of dronedarone.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Dronedarone; Electrocardiography; Heart Rate; Heart Ventricles; Male; Ventricular Function, Left | 2013 |
Dronaderone-induced phototoxicity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dermatitis, Phototoxic; Dronedarone; Drug Eruptions; Female; Humans; Middle Aged | 2013 |
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Dronedarone; Heart Conduction System; Heart Rate; Hospitalization; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Dronedarone versus amiodarone in preventing premature ventricular contractions in an in vitro model of "border zone".
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Heart; Heart Block; Heart Conduction System; Heart Ventricles; In Vitro Techniques; Myocardial Reperfusion Injury; Rabbits; Solutions; Ventricular Premature Complexes | 2014 |
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Topics: Amiodarone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; beta-Alanine; Clarithromycin; Dabigatran; Digoxin; Dronedarone; Drug Interactions; Humans; Models, Biological; Pyridines; Quinidine; Verapamil | 2014 |
[Appropriateness criteria for the treatment of atrial fibrillation with dronedarone: practical issues. An Italian cardiologists' expert opinion].
Topics: Amiodarone; Atrial Fibrillation; Dronedarone; Humans; Practice Guidelines as Topic | 2013 |
Non-standard dose dronedarone in treating atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Female; Humans; Male; Retrospective Studies; Treatment Outcome | 2014 |
Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Catheter Ablation; Dronedarone; Drug Administration Schedule; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Time Factors; Treatment Outcome | 2013 |
Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Dronedarone; Heart Conduction System; Heart Rate; Humans; Male | 2014 |
Assessment of dronedarone utilization using US claims databases.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Contraindications; Creatinine; Databases, Factual; Dronedarone; Drug Interactions; Drug Prescriptions; Drug Utilization Review; Female; Heart Failure; Hospitalization; Humans; Insurance Claim Review; Middle Aged; Retrospective Studies; Young Adult | 2014 |
Dronedarone, an amiodarone analog with improved anti-Leishmania mexicana efficacy.
Topics: Amiodarone; Animals; Calcium; Cells, Cultured; Dronedarone; Ergosterol; Homeostasis; Leishmania mexicana; Membrane Potential, Mitochondrial; Mice; Trypanosoma cruzi | 2014 |
Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Dronedarone; Evidence-Based Medicine; Heart Rate; Humans; Practice Guidelines as Topic; Recurrence; Reproducibility of Results; United States | 2014 |
Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cohort Studies; Dronedarone; Emergency Service, Hospital; Female; Health Resources; Health Services; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; United States; Young Adult | 2014 |
The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.
Topics: Adrenergic Antagonists; Amiodarone; Animals; Arenaviruses, New World; Bunyaviridae; Calcium Channel Blockers; Cell Line; Dronedarone; Ebolavirus; Humans; Lassa virus; Marburgvirus; Potassium Channel Blockers; Sodium Channel Blockers; Verapamil; Vesicular stomatitis Indiana virus; Virus Internalization | 2014 |
Safety of dronedarone in routine clinical care.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Failure; Humans; Liver Failure; Male | 2014 |
Dronedarone: "real-world" data vis-à-vis data from randomized clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2014 |
Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Hospitalization; Humans; Incidence; Randomized Controlled Trials as Topic; Secondary Prevention | 2014 |
Dronedarone: an option in the treatment of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Dronedarone; Humans; Hypertension; Male; Middle Aged; Tachycardia, Ventricular; Ventricular Premature Complexes | 2013 |
Editorial: advances in the therapy of atrial fibrillation: incrementally progressive but not without missteps.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Design; Humans; Pyrrolidines | 2014 |
Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation.
Topics: Alanine Transaminase; Amiodarone; Animals; Anti-Arrhythmia Agents; bcl-2-Associated X Protein; Disease Models, Animal; Dronedarone; Fatty Acids; Fatty Liver; Liver; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria, Liver; Oxidation-Reduction; Oxygen Consumption; Palmitic Acid; Palmitoylcarnitine; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2014 |
Lawsuit filed against Actavis over generic heart drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Delaware; Dronedarone; Drug Industry; Drugs, Generic; Patents as Topic | 2014 |
Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Embolism; Humans; Pyrrolidines; Stroke | 2014 |
Pharmacokinetics of dronedarone in rat using a newly developed high-performance liquid chromatographic assay method.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Dronedarone; Liquid-Liquid Extraction; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2014 |
Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Binding Sites; Dronedarone; Oocytes; Potassium Channels, Inwardly Rectifying; Protein Binding; Xenopus laevis | 2014 |
Significant tacrolimus and dronedarone interaction in a kidney transplant recipient.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Drug Interactions; Electrocardiography; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Tacrolimus | 2014 |
In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Dose-Response Relationship, Drug; Dronedarone; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart Atria; Heart Rate; Humans; Models, Cardiovascular; Mutation; Numerical Analysis, Computer-Assisted; Recurrence; Time Factors; Treatment Outcome | 2014 |
Systematic evaluation of plasma phospholipids for reliable and precise determination of dronedarone and desbutyldronedarone by LC-MS/MS.
Topics: Amiodarone; Chromatography, Liquid; Dronedarone; Mass Spectrometry; Phospholipids; Sensitivity and Specificity | 2014 |
Developing a list of high-alert medications for patients with chronic diseases.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Amiodarone; Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cytostatic Agents; Digoxin; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Eplerenone; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Methotrexate; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone | 2014 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Female; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Sotalol | 2014 |
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Dronedarone; Drug Substitution; Female; Flecainide; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Propafenone; Sotalol | 2015 |
Toxic Epidermal Necrolysis During Dronedarone Treatment: First Report of a Severe Serious Adverse Event Of A New Antiarrhythmic Drug.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Dronedarone; Fatal Outcome; Female; Heart Rate; Humans; Multiple Organ Failure; Severity of Illness Index; Stevens-Johnson Syndrome; Time Factors | 2015 |
Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Dronedarone; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Female; Rabbits; Ventricular Fibrillation | 2015 |
Effects of dronedarone on ventricular repolarization and repolarization dynamics in patients with preserved left ventricular systolic function.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Systole; Ventricular Function, Left | 2015 |
Torsade de pointes tachycardia in a patient on dronedarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Female; Humans; Torsades de Pointes | 2015 |
Preparation of solid dispersion of dronedarone hydrochloride with Soluplus(®) by hot melt extrusion technique for enhanced drug release.
Topics: Amiodarone; Chemistry, Pharmaceutical; Dronedarone; Drug Liberation; Hot Temperature; Hydrogen-Ion Concentration; Molecular Structure; Polyethylene Glycols; Polyvinyls; Solid Phase Extraction; Technology, Pharmaceutical | 2015 |
Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Topics: Aged; Amiodarone; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dronedarone; Female; Glomerular Filtration Rate; Healthy Volunteers; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Registries; Time Factors; Treatment Outcome | 2015 |
Diffuse alveolar damage in a patient receiving dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Diagnosis, Differential; Dronedarone; Female; Humans; Lung Diseases, Interstitial; Pulmonary Alveoli; Tomography, X-Ray Computed | 2015 |
Synthesis and characterization of new related substances of the antiarrhythmic drug dronedarone hydrochloride.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chemistry Techniques, Analytical; Chromatography, Liquid; Chromatography, Thin Layer; Dronedarone; Drug Contamination; Drug Design; Hydrogen; Magnetic Resonance Spectroscopy; Mass Spectrometry; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared | 2015 |
Reduced Food-Effect on Intestinal Absorption of Dronedarone by Self-microemulsifying Drug Delivery System (SMEDDS).
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Castor Oil; Dogs; Dronedarone; Drug Delivery Systems; Emulsions; Food-Drug Interactions; Glycerides; Glycerol; Intestinal Absorption; Male; Polyethylene Glycols; Polysorbates; Surface-Active Agents | 2015 |
Acute renal failure in patients treated with dronedarone or amiodarone: a large population-based cohort study in Italy.
Topics: Acute Kidney Injury; Aged; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Dronedarone; Female; Humans; Italy; Male; Proportional Hazards Models; Retrospective Studies | 2015 |
Dronedarone does not affect infarct volume as assessed by magnetic resonance imaging in a porcine model of myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Biomarkers; Coronary Vessels; Disease Models, Animal; Dronedarone; Electrocardiography; Hemodynamics; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Myocardial Infarction; Swine; Ventricular Function, Left | 2015 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; Humans; Male; Patient Admission; Pennsylvania; Phenethylamines; Recurrence; Retrospective Studies; Sotalol; Stroke; Sulfonamides | 2016 |
Impact of Food and Drug Administration hepatotoxicity warning on prescribing and monitoring of dronedarone in a tertiary teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chemical and Drug Induced Liver Injury; Dronedarone; Drug Labeling; Drug Monitoring; Female; Hospitals, Teaching; Humans; Liver Function Tests; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Tertiary Care Centers; United States; United States Food and Drug Administration | 2015 |
Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Topics: Amiodarone; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Dronedarone; Humans; Microsomes, Liver | 2016 |
Docetaxel Induced Sclerosing Cholangitis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Amiodarone; Anilides; Anti-Arrhythmia Agents; Antineoplastic Agents; Carbazoles; Carvedilol; Cholangitis, Sclerosing; Docetaxel; Dronedarone; Drug Interactions; Humans; Leuprolide; Male; Nitriles; Propanolamines; Taxoids; Tosyl Compounds | 2015 |
Organising pneumonia due to dronedarone.
Topics: Aged; Amiodarone; Dronedarone; Humans; Lung; Male; Pneumonia | 2015 |
Identification and characterization of stress degradation products of dronedarone hydrochloride employing LC-UV/PDA, LC-MS/TOF and MS(n) studies.
Topics: Amiodarone; Chromatography, Liquid; Dronedarone; Spectrophotometry, Ultraviolet; Tandem Mass Spectrometry | 2016 |
Distinctive property and pharmacology of voltage-gated sodium current in rat atrial vs ventricular myocytes.
Topics: Amiodarone; Animals; Cells, Cultured; Disease Models, Animal; Dronedarone; Heart Atria; Heart Ventricles; Myocytes, Cardiac; Patch-Clamp Techniques; Rats; Sodium Channel Blockers; Voltage-Gated Sodium Channels | 2016 |
Short-term effects of oral dronedarone administration on cardiac function, blood pressure and electrocardiogram in conscious telemetry dogs.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Dogs; Dronedarone; Electrocardiography; Female; Heart; Male; Telemetry | 2016 |
Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
Topics: Activation, Metabolic; Amiodarone; Animals; Anti-Arrhythmia Agents; Cell Line; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decarboxylation; Dronedarone; Humans; Insecta; Kinetics; Microsomes; Models, Molecular; Molecular Structure; NADP; Oxidation-Reduction; Prodrugs; Recombinant Proteins; Substrate Specificity | 2016 |
The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology.
Topics: Aged; Amiodarone; Atrial Function; Calcium; Calcium Signaling; Cardiovascular Agents; Dronedarone; Drug Therapy, Combination; Female; Heart Atria; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Contraction; Myocytes, Cardiac; Ranolazine; Sarcomeres; Ventricular Function | 2016 |
The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats.
Topics: Administration, Intravenous; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Area Under Curve; Biological Availability; Dronedarone; Hyperlipidemias; Injections, Intraperitoneal; Male; Poloxamer; Protein Binding; Rats, Sprague-Dawley | 2016 |
Dronedarone and Amiodarone Induce Dyslipidemia and Thyroid Dysfunction in Rats.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Dyslipidemias; Lipid Metabolism; Lipids; Liver; Male; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; Thyroid Gland; Thyroxine; Triiodothyronine; Vasodilator Agents | 2016 |
The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Prescriptions; Drug Utilization; England; Flecainide; Humans; Retrospective Studies; Sotalol | 2016 |
The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Dronedarone; Fatal Outcome; Humans; Male; Multiple Organ Failure; Nausea; Off-Label Use; Recurrence; Tachycardia, Ventricular; Treatment Failure | 2016 |
Convergent Synthesis of Dronedarone, an Antiarrhythmic Agent.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Molecular Structure | 2016 |
Clinical Experience of Prescribing Dabigatran Etexilate With Dronedarone: The Role of Therapeutic Drug Monitoring.
Topics: Adult; Aged; Amiodarone; Antithrombins; Dabigatran; Dronedarone; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male | 2016 |
Long-term adherence to dronedarone in patients with atrial arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Female; Follow-Up Studies; Humans; Male; Patient Compliance; Time Factors; Treatment Outcome | 2016 |
Rise and fall of dronedarone: the need for new drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone | 2016 |
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Treatment Outcome | 2017 |
Bioanalytical Method Validation for Dronedarone and Duloxetine in Blood Serum.
Topics: Amiodarone; Chromatography, High Pressure Liquid; Dronedarone; Duloxetine Hydrochloride; Humans; Serum | 2017 |
Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Disease Models, Animal; Dronedarone; Drug Interactions; Electrocardiography; Heart Conduction System; Rabbits; Ventricular Fibrillation | 2017 |
Dronedarone Modulates M1 and M3 Muscarinic Receptors with Subtype Selectivity, Functional Selectivity, and Probe Dependence.
Topics: Allosteric Regulation; Amiodarone; Animals; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dronedarone; Receptor, Muscarinic M1; Receptor, Muscarinic M3 | 2017 |
Molecular modeling, simulation and docking study of ebola virus glycoprotein.
Topics: Amino Acid Sequence; Amiodarone; Dronedarone; Ebolavirus; Glycoproteins; Intrinsically Disordered Proteins; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Structure, Secondary; Viral Proteins; Virion | 2017 |
Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay.
Topics: Aminoglycosides; Amiodarone; Bayes Theorem; Biological Transport; Cell Survival; Chemical and Drug Induced Liver Injury; Databases, Chemical; Dronedarone; Estradiol; Fidaxomicin; HEK293 Cells; Humans; Models, Molecular; Multidrug Resistance-Associated Proteins; Quantitative Structure-Activity Relationship; Suramin | 2017 |
Thyroid hormone induce a p53-dependent DNA damage through PI3K/Akt activation in sperm.
Topics: Adult; Amiodarone; Animals; Chromones; DNA Damage; Dronedarone; Enzyme Activation; Enzyme Inhibitors; Humans; Male; Mice, Inbred C57BL; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Receptors, Thyroid Hormone; Signal Transduction; Sperm Motility; Spermatozoa; Thyroxine; Tumor Suppressor Protein p53 | 2017 |
Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Dronedarone; Heart Atria; Humans; Refractory Period, Electrophysiological; Time Factors | 2017 |
Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Animals; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D6 Inhibitors; Dronedarone; Drug Interactions; Male; Models, Biological; Propanolamines; Rats, Sprague-Dawley; Substrate Specificity | 2018 |
Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cardiovascular Diseases; Dronedarone; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests | 2017 |
Dronedarone produces early regression of myocardial remodelling in structural heart disease.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrial Remodeling; Dronedarone; Heart Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; Positron Emission Tomography Computed Tomography; Rats; Rats, Inbred SHR | 2017 |
Drug-Drug Interactions between Atorvastatin and Dronedarone Mediated by Monomeric CYP3A4.
Topics: Allosteric Regulation; Allosteric Site; Amiodarone; Animals; Atorvastatin; Binding Sites; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Dronedarone; Drug Interactions; Humans; Kinetics; Models, Molecular; Molecular Dynamics Simulation; NADPH-Ferrihemoprotein Reductase; Protein Binding; Protein Conformation; Rats | 2018 |
DNA damage-induced apoptosis and mitogen-activated protein kinase pathway contribute to the toxicity of dronedarone in hepatic cells.
Topics: Amiodarone; Apoptosis; Cell Survival; DNA Damage; Down-Regulation; Dronedarone; Hep G2 Cells; Hepatocytes; Humans; Mitogen-Activated Protein Kinases; Signal Transduction | 2018 |
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Dronedarone; Female; Flecainide; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Propafenone; Retrospective Studies; Sotalol | 2018 |
Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure.
Topics: Amiodarone; Animals; Benzofurans; Calcium; Chagas Disease; Chlorocebus aethiops; Dose-Response Relationship, Drug; Dronedarone; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Mitochondria; Oxidoreductases; Trypanocidal Agents; Trypanosoma cruzi; Vero Cells | 2018 |
Re-gaining confidence in contemporary dronedarone use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone | 2018 |
Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Cohort Studies; Dronedarone; Female; Humans; Male; Middle Aged | 2018 |
Do not condemn solely dronedarone for acute liver injury: It's a class effect.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Liver | 2018 |
Influence of Amiodarone and Dronedarone on the Force-Interval Dependence of Rat Myocardium.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cross-Sectional Studies; Dronedarone; Male; Myocardium; Rats; Rats, Wistar | 2018 |
Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Female; Humans; Neoplastic Stem Cells; Ovarian Neoplasms | 2018 |
Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Hyperthyroidism; Male; Middle Aged; Prospective Studies | 2018 |
Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atrial myopathy of patients with atrial fibrillation? A provocative hypothesis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Embolic Stroke; Humans; Muscular Diseases | 2020 |
Dramatic reduction of ventricular tachycardia burden after dronedarone plus mexiletine treatment in a patient refractory to hybrid ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Dronedarone; Drug Therapy, Combination; Humans; Male; Mexiletine; Middle Aged; Tachycardia, Ventricular; Treatment Outcome | 2020 |
Inhibitory Effects of Dronedarone on Small Conductance Calcium Activated Potassium Channels in Patients with Chronic Atrial Fibrillation: Comparison to Amiodarone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Dronedarone; Female; Heart Atria; HEK293 Cells; Humans; Male; Middle Aged; Myocytes, Cardiac; Potassium Channels; Small-Conductance Calcium-Activated Potassium Channels | 2020 |
Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Humans; Male; Optic Nerve Diseases; Vision Disorders; Visual Acuity; Visual Fields | 2020 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Propafenone; Retrospective Studies; Rivaroxaban; Taiwan | 2021 |
Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzofurans; Cell Line; Dronedarone; Drug Interactions; HEK293 Cells; Humans; Organic Anion Transporters, Sodium-Independent; Rivaroxaban | 2021 |
Amiodarone, Unlike Dronedarone, Activates Inflammasomes via Its Reactive Metabolites: Implications for Amiodarone Adverse Reactions.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cell Line; Dronedarone; Hepatocytes; Humans; Inflammasomes; Macrophages; THP-1 Cells | 2021 |
Treatment of Postoperative New Onset Atrial Fibrillation with Repolarization Delaying Agents after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Dronedarone; Humans; Treatment Outcome | 2021 |
Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Medicare; Physicians; United States | 2021 |
International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; Humans; Male | 2022 |
[The Chinese expert recommendations on the clinical use of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; China; Dronedarone; Humans | 2021 |
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.
Topics: Adonis; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Humans; Pharmaceutical Preparations | 2022 |
Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Hemorrhage; Humans; Rivaroxaban | 2022 |
Effects of amiodarone, amioder, and dronedarone on Trichomonas vaginalis.
Topics: Amiodarone; Dronedarone; Female; Humans; Metronidazole; Trichomonas Infections; Trichomonas vaginalis; Trichomonas Vaginitis | 2022 |
A value-based budget impact model for dronedarone compared with other rhythm control strategies.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Sotalol | 2023 |
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dronedarone; Humans; Ischemic Stroke; Propafenone; Stroke | 2023 |
Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Sotalol; Stroke Volume; Ventricular Function, Left; Veterans | 2023 |